Bio-Rad Laboratories
Annual Report 2020

Plain-text annual report

Bio-Rad Laboratories Annual Report 22Letter to StockhoLderS If I had to describe 2020 overall, I would say it was a year to remember… and a year to forget. The year started out well enough, but went off course almost immediately and in a most unprecedented way, with the arrival of COVID-19, changing the priorities of many of our customers. In the March to April time frame, the outlook for the year looked bleak as the pandemic took over, but we managed to persevere and ended the year ahead of our original plan. We reported sales of $2.5 billion, a 10.3 percent increase over last year, on a constant currency basis, with an underlying operating income of $411.0 million, representing 16.1 percent of sales. Along with many other companies in healthcare, we quickly refocused our efforts to aid in the battle against the pandemic. Our first task was to set out three near-term principles to govern our activities for this very unique year. On top of our list was the safety of our employees. We transitioned as many people as possible to work from home, and we reconfigured and monitored access to our facilities to ensure that those in the workspace were safe. As you might imagine, since the onset of the pandemic, we have seen a number of COVID-19 cases within our own Bio-Rad bubble. Of those employees who have become ill, we are extremely thankful that all have recovered or are currently in recovery. This is a great achievement given the state of the world pandemic. The next priority was to serve our customers, adapting to the dynamics of very altered supply and demand landscapes. The operational challenges that confronted us were considerable. Our supply chain was severely impacted in the early days of the pandemic when critical suppliers categorized as non-essential businesses by government entities were being shut down just as we were scaling up the manufacture of critical instruments. As we ironed out these problems, we also worked to meet increased demand. We relocated the manufacture of certain products to optimize utilization and capabilities present in our various manufacturing locations, while also temporarily idling others. 2020 ProdUct SPotLIGht : coVId-19 PandemIc Covid-19 BeSt In cLaSS SenSItIVIty & accUracy Bio-Rad offers a range of products to join in the fight against COVID-19 including diagnostic screening of the virus, confirmation of test results, surveillance, as well as products that support therapy and vaccine research and development. From molecular testing using real-time PCR and Droplet Digital PCR technology to immunology assays, our products offer best in class sensitivity and accuracy. Our offering primarily consists of instruments, reagents, and consumables that are needed to detect the virus either in a clinical or a community setting. These core products are used for detection of the virus by polymerase chain reaction, or PCR, an accurate and sensitive method of molecular testing. Early in 2020, our Platelia SARS-CoV-2 Total Ab Assay (shown directly above) was the first total antibody test to receive Emergency Use Authorization (EUA) from the FDA to help determine an individual’s immune status to this coronavirus. The test can be used manually or on an automated immunoassay platform such as our EVOLIS System (shown upper left), which offers high throughput processing and sample traceability. Also in 2020, we received another EUA from the FDA for our SARS-CoV-2 Droplet Digital PCR (ddPCR ) Kit, which runs on our Droplet Digital PCR platforms. Our Droplet Digital PCR technology is proving to offer great value in detecting very low levels of the virus. This technology is being used by some diagnostic labs for improved sensitivity, but it has also found value in monitoring community wastewater streams to pinpoint areas of outbreak. Together, these products support the many efforts to address the COVID-19 pandemic, reflecting Bio-Rad’s ongoing commitment to improving healthcare for all. 2020 ProdUct SPotLIGht : cFX oPUS SyStemS CFX opus systems an eVoLUtIon oF QUantItatIVe Pcr Our CFX Opus Systems represent the next generation of our CFX Real-Time PCR family of quantitative PCR (qPCR) platforms. Introduced in 2020, the CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems offer the same optical design that is used across our portfolio of CFX products, but the Opus Systems offer enhanced usability with features designed for academic, commercial, and biopharma labs conducting research, process development, and quality control. Providing reliability our customers can depend on, the Opus Systems feature enhanced connectivity options including BR.io, Bio-Rad’s new cloud platform that enables users to design experiments, analyze data, and access their experiments remotely. BR.io offers seamless data transfer and the ability for users to monitor instrument status from any internet connection, with no software installation required. Used in research and genomic testing as well as in pathogen detection and infectious disease testing, the Opus platforms offer a simplified qPCR experience delivering a robust solution to meet the needs of our customers, helping them find answers to complex biological questions. Letter to StockhoLderS For our part, the pandemic product focus has largely been around instruments and reagents needed to detect the virus either in a clinical or a community setting. Our core products are instruments used for detection of the virus by a method called polymerase chain reaction, or PCR. This is a very accurate and sensitive method and today is considered the gold standard for molecular testing. We are well known for our products in this area and, as a result, were able to exponentially increase production to meet the unanticipated demand, not only for instruments, but also for some of the associated reagents. In record time, we were also able to introduce a serology test, which is useful for determining an individual’s immune status to this coronavirus. We were fortunate to have an assay, developed in 2004, when the predecessor to the COVID-19 virus (SARS) first appeared, and we were able to modify and repurpose the original test into a robust assay for SARS-CoV-2, the virus associated with COVID-19. In addition, we introduced quality controls for use in the antibody and molecular testing of SARS-CoV-2. These controls provide laboratories with an unbiased independent assessment of the laboratory’s test system for greater confidence in patient test results. In addition, our Droplet Digital PCR technology is proving to be of great value when there is need to detect very low levels of the virus. Not only is this technology being used by some diagnostic labs for improved sensitivity, but it has also found value in monitoring community wastewater streams to pinpoint areas of outbreak for advanced surveillance. Finally, adding to our roster of products being used in the battle against COVID-19, in early 2021 we introduced Bio-Plex Pro Human IgG SARS-CoV-2 Serology Assays, for research use only. This qualitative multiplex immunoassay kit detects IgG antibodies against four SARS-CoV-2 antigens, helping vaccine developers determine therapeutic efficacy, from development through all clinical evaluation phases. Our Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits were also granted Emergency Use Authorization by the FDA in 2021, providing labs with access to sensitive and reliable qPCR tests to help guide patient treatment decisions. Our third priority in 2020 was to not lose sight of the longer term. In spite of this unusual year, I am pleased to share that we have continued to make progress on all of our operational improvements planned for 2020. In 2017, we communicated a goal to achieve higher profit margins and improved cash flow. I am happy to 3 Letter to StockhoLderS report that this goal was achieved, and more, by the end of 2020. While most of the overage is due to gains associated with our COVID-19 related products and reduced travel during the year, our underlying progress is something we feel is sustainable and forms a good base from which to grow. At the end of 2020, we communicated our outlook for the next three years, which projects further growth and margin expansion going forward. We are well positioned in the growing markets of life science and healthcare. Our broad portfolio of products and technologies provides us with innumerable opportunities to introduce new, innovative products. We also see opportunity to continue to improve our operating margins through several targeted operational initiatives. While much of our new product focus during the year centered around COVID-19, there were a number of other notable introductions including the QX ONE Droplet Digital PCR System that extends the market for this powerful technology. The system integrates the entire workflow and provides us access to higher-volume users, such as the increasingly important biopharma customer segment. We also introduced an updated line of real-time thermal cyclers referred to as the “CFX Opus Systems”. They represent the next generation of our CFX Real-Time PCR platforms, offering enhanced usability for academic research as well as commercial and biopharma labs. Our latest imaging system, the GelDoc Go Gel Imaging System—another notable introduction in 2020—is a personal benchtop device offering sensitivity and reliability in a compact system. During the year we added single-cell analysis capabilities with the acquisition of Celsee, extending our reach into the rapidly growing world of precision medicine and single-cell analysis. This technology helps scientists isolate, analyze, and interpret cellular behavior, at the individual cell level. Also of note, we were pleased to have Dara Wright join our organization, leading our Clinical Diagnostics Group. Dara brings a wealth of experience and has a proven track record of success. She replaces John Hertia, who retired at the end of 2019. We would like to thank John for his many contributions to Bio-Rad over the years. We will continue to work on other opportunities where we might contribute to battling COVID-19. The dramatic dip we saw in sales early in the year has given way to a slow steady return to more normal sales volumes, as researchers return to labs and the healthcare system rebalances between a COVID and a non-COVID environment. 4 2020 ProdUct SPotLIGht : QX one For waStewater teStInG QX oNe PrecISIon & accUracy In one InteGrated SyStem Introduced in 2020, the QX ONE Droplet Digital PCR System automates Bio-Rad’s Droplet Digital PCR (ddPCR ) technology into a single and easy-to- use integrated platform. Designed for biopharmaceutical drug development, manufacturing quality control, and other highly critical testing environments, the high-throughput system automates each step of the ddPCR workflow: droplet generation, amplification, and droplet reading, offering continuous operation that can analyze up to 480 samples in a single day. Helping to monitor COVID-19 in communities, the QX ONE Droplet Digital PCR System and the QX200 Droplet Digital PCR System are helping officials detect, track, and trace the spread of the virus in wastewater (sewage), creating an early warning system. Analyzing the wastewater of a community using Droplet Digital PCR can predict an outbreak several days in advance of anyone showing symptoms, detecting both symptomatic and asymptomatic individuals in the population or community. 2020 ProdUct SPotLIGht : GeLdoc Go GeL ImaGInG SyStem GeLdoC Go PerSonaL BenchtoP ImaGInG The GelDoc Go Imaging System is the latest addition to our GelDoc product line, offering researchers a way to visualize and document molecules quickly and easily with an instrument that is compact enough to fit right on a benchtop. Easy to use, the system produces crisp, publication-ready images, helping researchers better understand the quantity and quality of nucleic acids and proteins with just a few taps on the integrated touchscreen, saving time and providing results quickly. Offering sensitivity, performance, and flexibility, the advanced optical design provides a large screen area to image one large gel or up to four mini gels at a time. Researchers can image gels using their preferred nucleic acid or protein stains or with Bio-Rad’s Stain-Free technology. Image Lab Touch Software and a built-in USB port makes it easy to transfer data to another network. Moving research forward quickly and easily, the GelDoc Go System brings high quality imaging to your fingertips. Letter to StockhoLderS After a year like this, it is hard to predict exactly what 2021 has in store for us. We plan for the pandemic to be with us for most of the year ahead, with gradual relief coming as widespread vaccination gets the world closer to herd immunity and a return to normal. One encouraging observation over the past year is that the remote work environment can be a productive one. Consequently, we will likely see an increase in remote work, balanced with the connectivity and collaboration that is optimal in a physically co-located environment. The communication tools and technology we have adopted over the past twelve months will, no doubt, also be embedded as a valuable way to more efficiently and rapidly respond to our customers. As for the business in general, we look forward to another year of progress, both internally, as we continue to drive efficiency and effectiveness throughout the organization, and externally, as we better serve our expanding markets. The pandemic has certainly reinforced the value of biological science, demonstrated by the ability of the biopharma community to develop and introduce a vaccine in less than a year. It has also reinforced the value of diagnostics, which have been so critical in managing this situation. These are the areas in which we participate, a great place to be in this day and age. In closing, I want to take this opportunity to recognize our employees around the world who went the extra mile to serve our customers in 2020 and beyond. Their contributions have allowed us to continue to grow and have helped our customers to advance discovery and improve lives. Thank you for your interest in Bio-Rad. Norman Schwartz CHAIRmAN OF THE BOARD, PRESIDENT AND CEO 7 2020 Financial Highlights 2020 SALES BY GROUP 2020 SALES BY GROUP 2020 SaLeS By GroUP (IN MILLIONS) (IN MILLIONS) (IN MILLIONS) 2020 SALES BY REGION 2020 SaLeS By reGIon 2020 SALES BY REGION 48% Life Science 51% $1,231.8 Clinical Diagnostics $1,305.2 51% Clinical Diagnostics $1,305.2 48% Life Science $1,231.8 1% Other 1% Other 21% Pacific Rim 21% Pacific Rim 45% Americas 45% Americas 34% Europe 34% Europe NET SALES (IN MILLIONS) NET SALES net SaLeS (IN MILLIONS) (IN MILLIONS) CASH FLOW FROM OPERATIONS CASH FLOW FROM OPERATIONS caSh FLow From oPeratIonS (IN MILLIONS) (IN MILLIONS) (IN MILLIONS) BASIC EARNINGS PER SHARE BASIC EARNINGS PER SHARE 2016 2016 $ 2,068.2 $ 2,068.2 2016 2016 $ 216.1 $ 216.1 2016 2016 $ 0.88 $ 0.88 2017 2017 $ 2,160.2 $ 2,160.2 2017 2017 $ 104.1 $ 104.1 2017 2017 $ 4.12 $ 4.12 2018 2018 $ 2,289.4 $ 2,289.4 2018 2018 $ 285.5 $ 285.5 2018 2018 $ 12.25 $ 12.25 2019 2019 $ 2,311.7 $ 2,311.7 2019 2019 $ 457.9 $ 457.9 2019 2019 $ 58.93 $ 58.93 2020 2020 $ 2,545.6 $ 2,545.6 2020 2020 $ 575.3 $ 575.3 2020 2020 $ 127.86 $ 127.86 BIO-RAD, DDPCR, DROPLET DIGITAL PCR, QX200, QX ONE, PLATELIA, EVOLIS, RELIANCE, GELDOC, BIO-PLEX PRO, CFX, CFX OPUS are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. 8 2020 at a glance 2016 2017 2018 2019 2020(in millions, except for return on sales and per share data)Net Sales $ 2,068.2 $ 2,160.2 $ 2,289.4 $ 2,311.7 $ 2,545.6Gross Profit $ 1,138.4 $ 1,187.7 $ 1,223.2 $ 1,257.0 $ 1,437.8Operating Income (Loss) $ 55.7 $ 119.3 $ (103.3) $ 229.7 $ 411.0Cash Flow from Operations $ 216.1 $ 104.1 $ 285.5 $ 457.9 $ 575.3FIVe-year record$ 2,068.22016$ 2,160.22017$ 2,289.42018$ 2,311.72019NET SALES (IN MILLIONS)$ 2,545.62020$ 216.12016$ 104.12017$ 285.52018$ 457.92019CASH FLOW FROM OPERATIONS (IN MILLIONS)$ 0.882016$ 4.122017$ 12.252018$ 58.932019BASIC EARNINGS PER SHARE$ 127.862020$ 575.320202020 SALES BY REGION45%Americas21%Pacific Rim34%Europe2020 SALES BY GROUP (IN MILLIONS)51%Clinical Diagnostics$1,305.248%Life Science$1,231.81%Other$ 2,068.22016$ 2,160.22017$ 2,289.42018$ 2,311.72019NET SALES (IN MILLIONS)$ 2,545.62020$ 216.12016$ 104.12017$ 285.52018$ 457.92019CASH FLOW FROM OPERATIONS (IN MILLIONS)$ 0.882016$ 4.122017$ 12.252018$ 58.932019BASIC EARNINGS PER SHARE$ 127.862020$ 575.320202020 SALES BY REGION45%Americas21%Pacific Rim34%Europe2020 SALES BY GROUP (IN MILLIONS)51%Clinical Diagnostics$1,305.248%Life Science$1,231.81%OtherUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 94-1381833 (I.R.S. Employer Identification No.) 1000 Alfred Nobel Drive, Hercules, (Address of principal executive offices) California 94547 (Zip Code) Registrant's telephone number, including area code (510) 724-7000 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Class A Common Stock Par Value $0.0001 per share Class B Common Stock Par Value $0.0001 per share Securities registered pursuant to Section 12(g) of the Act: NONE Trading Symbols BIO BIOb Name of Each Exchange on Which Registered New York Stock Exchange New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes  ☒ No ☐ Yes ☒ No Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ¨ No ☒ Yes ¨ No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-accelerated file ☒ ☐ Accelerated filer Smaller reporting company Emerging growth company ☐ ☐ ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ ☒ ☐ Yes ☒ No As of June 30, 2020, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's Class A Common Stock held by non-affiliates was approximately $9,501,744,303 and the aggregate market value of the registrant's Class B Common Stock held by non- affiliates was approximately $85,986,722. As of February 10, 2021, there were 24,768,670 shares of Class A Common Stock and 5,075,386 shares of Class B Common Stock outstanding. (1) Definitive Proxy Statement to be mailed to stockholders in connection with the registrant's 2021 Annual Meeting of Stockholders (specified portions) III Documents Incorporated by Reference Document Form 10-K Parts BIO-RAD LABORATORIES, INC. FORM 10-K DECEMBER 31, 2020 TABLE OF CONTENTS Part I. Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures Part II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Selected Financial Data Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Item 7A. Quantitative and Qualitative Disclosures About Market Risk Item 8. Financial Statements and Supplementary Data Item 9. Changes and Disagreements with Accountants on Accounting and Financial Disclosure Item 9A. Controls and Procedures Item 9B. Other Information Part III. Item 10. Directors, Executive Officers and Corporate Governance Item 11. Executive Compensation Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13. Certain Relationships and Related Transactions, and Director Independence Item 14. Principal Accountant Fees and Services Part IV. Item 15. Exhibits and Financial Statement Schedules Item 16. Form 10-K Summary Signatures 3 3 8 22 23 23 23 24 24 26 26 37 38 90 91 92 92 92 93 93 93 93 94 94 97 97 2 INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS Other than statements of historical fact, statements made in this Annual Report include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties. These forward-looking statements may also include statements regarding the impact of the COVID-19 pandemic on Bio- Rad’s results and operations and steps governments, universities, hospitals and private industry, including diagnostic laboratories, are taking or may take as a result of the pandemic. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including but not limited to the duration, severity and impact of the COVID-19 pandemic, global economic conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, reductions in government funding or capital spending of our customers, international legal and regulatory risks, supply chain issues, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under “Item 1A, Risk Factors” of this Annual Report. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. PART I. ITEM 1. BUSINESS General Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” and “our”) is a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Bio-Rad manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. We have direct distribution channels in over 36 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 36 countries, sales efforts are supplemented by distributors and agents. Description of Business Business Segments Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Our Life Science segment and our Clinical Diagnostics segment generated 49% and 51%, respectively, of our net sales for the year ended December 31, 2020. We generated approximately 39% of our consolidated net sales for the year ended December 31, 2020 from U.S. sales and approximately 61% from sales in our remaining worldwide markets. 3 Life Science Segment Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions. We are a leader in the life sciences market and develop, manufacture and market approximately 6,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of our products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. We focus on selected segments of the life sciences market in proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cellular biology and food safety. We estimate that the worldwide market that our portfolios can address for products in these selected segments of our addressable markets is approximately $14 billion. Our principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. These tools are typically used to separate, purify, characterize, or quantitate biological materials such as cells, proteins, and nucleic acids in the research laboratory or the biopharmaceutical manufacturing and quality control process, for food safety and science education and literacy. We are focused on the translational research market segment where our products help accelerate the timelines from discovery in the lab to the clinic and the patient. Clinical Diagnostics Segment Our Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Our products currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on the higher margin, higher growth segments of this market. We supply more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. We estimate that the worldwide sales for products in the markets we serve is approximately $16 billion. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or urine. Our products consist of reagents, instruments and software, typically provided to our customers as an integrated package to allow them to generate reproducible test results. Revenue in this business is highly recurring, as laboratories typically standardize test methodologies, which are dependent on a particular supplier’s equipment, reagents and consumable products. An installed base of diagnostic test systems therefore typically creates an ongoing source of revenue through the sale of test kits for each sample analyzed on an installed system. Our principal clinical diagnostic customers include hospital laboratories, diagnostic reference laboratories, transfusion laboratories and physician office laboratories. Raw Materials and Components We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical parts, computing and peripheral devices. Most of these materials and components are available from numerous sources, and while we have historically not experienced difficulty in securing adequate supplies, the impact of COVID-19 on our suppliers' operations has created some challenges in procuring materials. For more discussion relating to the impacts of the COVID-19 pandemic, please see “Item 1A, Risk Factors” to this Annual Report. In certain instances we acquire components and materials from a sole supplier. Due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. 4 Patents, Trademarks and Licenses We own over 2,200 U.S. and international patents and numerous trademarks. We also hold licenses under U.S. and foreign patents owned by third parties and pay royalties on the sales of certain products under these licenses. We view these patents, trademarks and license agreements as valuable assets; however, we believe that our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills rather than our patent, trademark and licensing positions. Seasonal Operations and Backlog Our business is not inherently seasonal. However, the European custom of concentrating vacation during the summer months usually tempers third quarter sales volume and operating income. For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs. Management has concluded that backlog information is not material to our business as a whole. Sales and Marketing We conduct our worldwide operations through an extensive direct sales force, employing approximately 880 direct sales and sales management personnel around the world. Our sales force typically consists of experienced industry professionals with scientific training, and we maintain a separate specialist sales force for each of our segments. We believe that this direct sales approach allows us to sell a broader range of our products that creates more brand awareness and long-term relationships with our customers. We also use a range of sales and marketing intermediaries (SMIs) in our international markets. The types of SMIs we utilize are distributors, agents, brokers and resellers. We have programs and policies in place with our SMIs to ensure their compliance with all applicable laws, including adhering to our anti-corruption standards to ensure a transparent sale to our customers. Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and research institutions; (2) hospital, public health and commercial laboratories; (3) other leading diagnostic manufacturers; and (4) leading companies in the biotechnology, pharmaceutical, chemical and food industries. Our sales are affected by a number of external factors. For example, a number of our customers, particularly in the Life Science segment, are substantially dependent on government grants and research contracts for their funding. Most of our international sales are generated by our wholly-owned international subsidiaries and their branch offices. Certain of these subsidiaries also have manufacturing operations. Bio-Rad’s international operations are subject to certain risks common to foreign operations in general, such as changes in governmental regulations, import restrictions and foreign exchange fluctuations. Competition The markets served by our product groups are highly competitive. Our competitors range in size from start-ups to large multinational corporations with significant resources and reach. We seek to compete primarily in market segments where our products and technology offer customers specific advantages over the competition. Our Life Science segment does not face the same competitors for all of its products due to the breadth of its product lines. Major competitors in this market include Becton Dickinson, GE Biosciences, Merck Millipore and Thermo Fisher Scientific. We compete primarily based on meeting performance specifications and offering comprehensive solutions. 5 Major competitors of our Clinical Diagnostics segment include Roche, Abbott Laboratories, Siemens, Danaher, Thermo Fisher, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh, Immucor and DiaSorin. We compete across a variety of attributes including service, quality and portfolio. Research and Development We conduct extensive research and development activities in all areas of our business, employing approximately 880 employees worldwide in these activities, including degreed scientists and technical support staff. Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future. Our research teams are continuously developing new products and new applications for existing products. In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry. Regulatory Matters The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of certain of our products (primarily diagnostic and donor screening products) are subject to regulation in the United States by the Center for Devices and Radiological Health (CDRH) and/or the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) and in other jurisdictions by state and foreign government authorities. FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance with FDA’s “good manufacturing practice” regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations. After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA enforces these requirements by inspection and market surveillance. The FDA has authority to take various administrative and legal actions against us for our, or our products’, failure to comply with relevant legal or regulatory requirements, including issuing warning letters, initiating product seizures, requesting or requiring product recalls or withdrawals, and other civil or criminal sanctions, among other things. We are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment. Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for certain medical products and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls and restrictions on reimbursement. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the European Union and other jurisdictions. 6 Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate. The environmental laws and regulations could also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. These regulatory requirements vary widely among countries. Human Capital Resources At Bio-Rad, we consider our employees to be our most valuable asset, and critical to the effective development, manufacture, sale, distribution and servicing of our vast array of products and services. Our employees are essential to satisfying our customers’ needs for products to advance science and healthcare. At December 31, 2020, we had approximately 8,000 employees, the overwhelming majority of which are full-time employees. Our employees are located throughout the world with roughly 45% in the Americas, 40% in Europe, the Middle-East and Africa, and 15% in Asia Pacific. Our employees are represented by more than 90 self-identified nationalities working in over 140 locations in 36 different countries around the world. Diversity, Equity and Inclusion At Bio-Rad, we recognize that diversity is a strength. Our differences offer new and unique ideas and perspectives to our organization. We foster a work culture that embraces the diverse experience and knowledge of every employee, creating an inclusive culture regardless of race, gender, age, sexual orientation, disability, or nationality. We have been purposeful in our efforts to hire, develop and retain diverse talent as well as in our efforts to create an inclusive culture. We actively encourage employee engagement and regularly solicit feedback regarding job satisfaction, career growth and development, collaboration, empowerment, ethics, and manager effectiveness. We use employee input to help our managers make focused and strategic commitments to improve and sustain engagement in their teams. Bio-Rad requires that all management and employees participate in ongoing training intended to increase awareness of the importance of a diverse and inclusive culture. Compensation and Benefits We provide a competitive total rewards program consisting of broad-based salary and bonus plans as well as annual management stock grants. These programs combine to recognize and reward performance based on individual, group, and overall company contributions. We provide competitive health and welfare programs which include medical, dental, vision and life insurance, a 401(k) plan, an employee stock purchase program, local pension plans, profit sharing, employee assistance, child and elder care programs, employee recognition and a host of other localized programs tied to the unique needs of our employees. Pay equity is an integral part of our compensation strategy at Bio-Rad. We have ongoing processes and protocols to help us pay each individual employee appropriately based on her or his skills, performance, experience, location, market practices, etc., regardless of race, gender and other non-performance related attributes. Health, Wellness and Safety The health and welfare of our employees is of the highest importance to Bio-Rad. We prioritize, manage, and carefully track safety performance at all locations globally and integrate sound safety practices in every aspect of our operations. We offer work site hazard evaluations, workplace safety surveys, safety equipment selection, safety program reviews, chemical and radiation exposure monitoring, safety training, and disposal of hazardous chemical, radioactive and infectious waste. In response to the COVID-19 pandemic and related mitigation measures, we implemented changes in our business in March 2020 in an effort to protect our employees and customers from 7 COVID-related exposures. For example, we installed physical barriers between and distanced our employees in production facilities, implemented extensive cleaning and sanitation processes for both production and office spaces and broad work-from-home initiatives for employees in our administrative functions. While Bio-Rad’s essential workers have continued to work at our facilities and provide vital service to our customers, most employees in our administrative functions have effectively worked remotely since mid-March 2020. We require employees to isolate and quarantine when appropriate to protect their fellow workers and deploy rapid COVID-19 testing when appropriate. Training and Talent Development We provide training programs for managers and employees to support their growth and development. Our management series of courses cover essential management and leadership learning to provide our managers with the necessary skills and experience needed to more effectively lead and develop their teams. In addition, available courses for employees help them to be more effective at work, enhance interpersonal effectiveness, and help them achieve their full potential. We also support employees’ professional development by providing an educational reimbursement program for qualified educational expenses. We have moved our learning and development efforts to a virtual platform in response to the global pandemic. Available Information Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended. The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including Bio-Rad, that file electronically with the SEC. The public can obtain any documents that we file with the SEC at http://www.sec.gov. Bio-Rad’s website address is www.bio-rad.com. We make available, free of charge through our website, our Form 10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the SEC. The information on our website is not part of this Annual Report on Form 10-K. ITEM 1A. RISK FACTORS In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this Annual Report. We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock. We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry or the trading price of our common stock. Please carefully consider the following discussion of significant factors, events and uncertainties that make an investment in our securities risky and provide important information for the understanding of the “forward-looking” statements discussed this Annual Report. In addition to the effects of the COVID-19 pandemic and resulting global disruptions on our business and operations discussed in this Annual Report, additional or unforeseen effects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks discussed below. 8 Business, Economic, Legal and Industry Risks Pandemics or disease outbreaks, such as the COVID-19 pandemic, have affected and could materially adversely affect our business, operations, financial condition, and results of operations. The COVID-19 pandemic is having and is expected to continue to have an adverse effect on the United States and global economies, as well as on aspects of our operations and those of third parties on whom we rely. The COVID-19 pandemic has impacted and, we expect, will continue to impact parts of our business, operations, financial condition and results of operations in a variety of ways. Although demand has increased for certain of our products being used in fighting the COVID-19 pandemic, we are experiencing a decrease in product demand with reduced sales activity and customer orders in a number of our businesses. Many of our customers have reduced or modified operations, resulting in labs, universities and other customers' facilities being closed or opened at reduced capacity, hospital visits have declined as people delay elective surgeries and avoid non-essential trips to the hospital, and routine diagnostic testing has slowed. Although certain locations have experienced an improvement in conditions related to the pandemic, we expect that parts of our business will continue to suffer negative impacts from the pandemic even as conditions improve in some locations. On the supply side, we are experiencing challenges with the supply of raw materials and components used in the production of our products, with suppliers operating at reduced or modified capacity and otherwise unable to meet our increased demand for raw materials and inputs to manufacture our products being used in fighting the COVID-19 pandemic. In addition, we are experiencing transportation challenges in moving goods across regions, including reduced freight availability as many airlines have significantly scaled back flight operations and increased freight surcharges due to reduced freight capacity. Countries have closed their borders and imposed travel restrictions and may continue to impose measures that restrict the movement of our goods. The invocation by the U.S. federal government of the Defense Production Act of 1950 with respect to our manufacturing operations, or the enforcement of comparable laws by other governmental entities, could disrupt our manufacturing and distribution operations. With respect to our personnel, as a critical health care supplier, we continue to keep certain essential production, distribution and service teams onsite working in manufacturing and supply chain facilities throughout the world. Although we are adhering to government mandated and Environmental, Health and Safety protocols, an outbreak of COVID-19 at one or more of our facilities could nonetheless cause shutdowns of facilities and a reduction in our workforce, which could dramatically affect our ability to operate our business and our financial results. The duration of the COVID-19 pandemic is unknown, even with the distribution of a vaccine, and it is difficult to predict the full extent of potential impacts the pandemic will have in the future on our business, operations, and financial results, or on our customers, suppliers, logistics providers, or on the global economy as a whole. . 9 Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition. We have significant international operations. We have direct distribution channels in over 36 countries outside the United States, and for the year ended December 31, 2020 our foreign entities generated 61% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements, labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign Corrupt Practices Act ("FCPA") and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions. For example, the United Kingdom's withdrawal from the European Union (commonly referred to as “Brexit”) could disrupt the free movement of goods, services and people between the United Kingdom and the European Union and result in increased regulatory, legal, labor and tax complexities. Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with laws and regulations, and our global policies and procedures. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the FCPA. Any future violations of the FCPA could result in more punitive actions by the SEC and DOJ and/or could harm our reputation with customers, either of which could materially adversely affect our business, results of operations and financial condition. See also our risk factors regarding the COVID-19 pandemic above and regarding government regulations and global economic conditions below. 10 The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively. The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition. We may not be able to grow our business because of our failure to develop new or improved products. Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point- of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. The COVID-19 pandemic may delay our ability to develop and introduce new products. We have experienced product launch delays in the past and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition. Breaches of our information systems could have a material adverse effect on our business and results of operations. We have experienced and expect to continue to experience attempts by computer programmers and hackers to attack and penetrate our layered security controls, like the December 2019 Cyberattack that was previously discussed in Item 7 of our Annual Report for the period ended December 31, 2019. Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Increased use of remote work arrangements and rapidly evolving work scenarios in response to the COVID-19 pandemic expose us to additional risk of cyberattack and disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not recognized until launched against a target, we may not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers have attempted to penetrate and will likely continue to attempt to penetrate our and our vendors’ information systems and, if successful, could misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce 11 channels, could also be disrupted, as they were in the December 2019 Cyberattack. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our information technology systems and our enterprise resource planning system (ERP) implementation below. If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed. Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable. Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service. We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency. Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes. We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our data security above and ERP implementation and events beyond our control below. We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition. As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition. 12 Changes in the market value of our position in Sartorius AG materially impact our financial results and might cause us to be deemed an investment company. Changes in the market value of our position in Sartorius AG may continue to materially impact our consolidated statements of income and other financial statements. A decline in the market value of our position in Sartorius AG could result in significant losses due to write-downs in the value of the equity securities. An increase in the market value of our position in Sartorius AG could result in a significant and favorable impact to net income independent of the actual operating performance of our business. As a result of the market value of our position in Sartorius AG, we might be deemed to be an “investment company” under Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), even though we are primarily engaged in a business other than that of investing, reinvesting, owning, holding or trading in securities. Because the Company might be deemed an investment company under the Investment Company Act based on the market value of our position in Sartorius AG alone, the Company has limited access to the capital markets and may not be able to obtain additional financing until it is determined that the Company is not an investment company. The Company does not believe it is an investment company and intends to continue to conduct our operations so that we will not be deemed an investment company. If the Company were deemed to be an investment company such determination could have a material adverse effect on our business. Our share price may change significantly based upon changes in the market valuation of Sartorius AG, and such change may be unrelated to the actual performance of our business. Non-operating income for a period may be significantly impacted by the timing of dividends paid by Sartorius AG, particularly in comparison to prior year periods. We may incur losses in future periods due to write-downs in the value of financial instruments. We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile, particularly in light of the COVID-19 pandemic, and the markets for these securities can be illiquid. The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations. We also have positions in equity securities, including our position in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities that we own could result in significant losses due to write-downs in the value of the equity securities. In addition, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses. We may experience difficulties implementing our new global enterprise resource planning system. We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties, as we already have with some of our earlier deployments. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. We expect to implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition. 13 Recent and planned changes to our organizational structure could negatively impact our business. We made significant changes to our organizational structure over the past few years. We have continued to reorganize aspects of our European operations since 2016, including the reorganization announced in February 2021. At the beginning of 2020, we restructured the Clinical Diagnostics segment based on functional groups rather than product line divisions. These changes may have unintended consequences, such as distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity. Risks relating to intellectual property rights may negatively impact our business. We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition. Global economic and geopolitical conditions could adversely affect our operations. In recent years, we have been faced with very challenging global economic conditions. The COVID-19 pandemic, as discussed above, is currently causing disruptions to global economic conditions. It is unknown how long such disruptions will continue and whether such disruptions will become more severe. A deterioration in the global economic environment may, and is currently, resulting generally in decreased demand for our products (other than with respect to certain of our products being used in fighting the COVID-19 pandemic), increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may, and currently is, also adversely affecting our suppliers, which could result in interruptions in supply in the future. Additionally, the United States and other countries, such as China and India, recently have imposed tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk factors regarding the COVID-19 pandemic and our international operations above and regarding government regulations below. Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition. Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and companies have a significant effect on the demand for our products. Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods. If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected. 14 Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition. There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include: • • The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage. In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets. Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates. To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected. If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products. We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition. Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution. 15 The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products. Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re- register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes regarding in vitro diagnostic devices and medical devices, which will require us to modify or re-register some products and will result in additional costs. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Brexit also will likely result in additional regulatory requirements associated with goods sold in the United Kingdom and will likely result in additional complexities and possible delays with respect to goods, raw materials and personnel moving between the United Kingdom and the European Union. In addition, new government administrations may interpret existing regulations or practices differently. For example, the Mexican health regulatory agency COFEPRIS in 2019 cited Bio-Rad’s Mexican subsidiary for operating practices that had been endorsed by a prior administration, which has impacted our ability to conduct our Clinical Diagnostics business in Mexico. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Certain tenders in China and India also are including local manufacturing preferences or requirements. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above. We are also subject to government regulation of the use and handling of a number of materials and controlled substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses. 16 We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions. As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could cause significant diversion of our management’s time and resources. If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur, as they have occurred in the past. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition. Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition. We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition. Lack of key personnel could hurt our business. Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business. 17 A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales. The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products. See also our risk factor regarding the COVID-19 pandemic above. We may have higher than anticipated tax liabilities. We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition. Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations. On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements. The tax effect of our position in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow. In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country. 18 Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition. Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations. We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition. Our debt may restrict our future operations. As of December 31, 2020, we have a revolving credit facility that provides for up to $200.0 million in borrowing capacity, $0.2 million of which has been utilized for domestic standby letters of credit. Our existing credit facility and agreements we may enter in the future, contain or may contain covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test. Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. As noted above, because the Company might be deemed an investment company under the Investment Company Act based on the market value of our position in Sartorius AG, the Company may not be able to access the capital markets or otherwise obtain additional financing until it is determined that the Company is not an investment company. The inability to obtain additional financing may have a negative impact on the Company’s existing business, our ability to grow our business, and our ability to make acquisitions. 19 We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws. We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example: • the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs; • U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes; • • • the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals; the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers. These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition. 20 Risks Related to Being a Public Company Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline. Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. Material weaknesses in our internal control over financial reporting have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline. General Business Risks Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition. We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years. These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, electricity outages, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business. Acts of terrorism, bioterrorism, violence or war, or public health issues such as the outbreak of a contagious disease like COVID-19 could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition. Risks Related to Our Common Stock A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest. We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors. As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company. 21 The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees. Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Certificate of Incorporation or the Bylaws (in each case, as may be amended from time to time) or (iv) any action asserting a claim against the Company or any of its directors, officers or other employees governed by the internal affairs doctrine of the State of Delaware. This choice of forum provision may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Company’s bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions. Application of the choice of forum provision may be limited in some instances by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the choice of forum provision will not apply to actions arising under the Exchange Act or the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, subject to a limited exception for certain “covered class actions.” There is uncertainty, particularly in light of current litigation, as to whether a court would enforce the choice of forum provision with respect to claims under the Securities Act. Our stockholders will not be deemed, by operation of the Company’s choice of forum provision, to have waived claims arising under the federal securities laws and the rules and regulations thereunder. ITEM 1B. UNRESOLVED STAFF COMMENTS None. 22 ITEM 2. PROPERTIES We own our corporate headquarters located in Hercules, California. The principal manufacturing and research locations for each segment are as follows: Segment Location Life Science Clinical Diagnostics Greater San Francisco Bay Area, California Singapore, Singapore Oxford, England Greater San Francisco Bay Area, California Irvine, California Greater Seattle Area, Washington Lille, France Greater Paris Area, France Nazareth-Eke, Belgium Cressier, Switzerland Dreieich, Germany Owned/Leased Owned/Leased Leased Leased Owned/Leased Leased Leased Owned Leased Leased Owned/Leased Owned/Leased Most manufacturing and research facilities also house administration, sales and distribution activities. In addition, we lease office and warehouse facilities in a variety of locations around the world. The facilities are used principally for sales, service, distribution and administration for both segments. ITEM 3. LEGAL PROCEEDINGS We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. 23 PART II. ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Information Concerning Common Stock Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the ticker symbols BIO and BIOb, respectively. On February 10, 2021, we had 174 holders of record of Class A Common Stock and 99 holders of record of Class B Common Stock. Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends. In November 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock (“Share Repurchase Program”). In July 2020, the Board of Directors authorized increasing the share repurchase program to allow the Company to repurchase up to an additional $200.0 million of stock. During the three months ended December 31, 2020, we did not purchase or otherwise acquire any shares of common stock. As of December 31, 2020, $273.1 million remained under the share repurchase program. See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and for securities authorized for issuance under equity compensation plans. 24 Stock Performance Graph The following graph compares the cumulative stockholder returns over the past five years for our Class A Common Stock, the S&P 400 MidCap Index and a selected peer group, assuming $100 invested on December 31, 2015, and reinvestment of dividends if paid: (1) The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher Scientific, Meridian Bioscience and PerkinElmer. Companies in our peer group reflect our participation in two different markets: life science research products and clinical diagnostics. No single public or private company has a comparable mix of products which serve the same markets. In many cases, only one division of a peer-group company competes in the same market as we do. Collectively, however, our peer group reflects products and markets similar to those of Bio-Rad. This stock performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed under these Acts. 25 DOLLARSBio-RadPeer Group (1)S&P MidCap 40020152016201720182019202050100150200250300350400450 ITEM 6. SELECTED FINANCIAL DATA BIO-RAD LABORATORIES, INC. Selected Financial Data (In thousands, except per share data) Net sales Cost of goods sold Gross profit Selling, general and administrative expense Research and development expense Impairment losses on goodwill and long- lived assets Interest expense Foreign currency exchange losses, net Change in fair market value of equity securities Other income, net Income before income taxes (Provision for) benefit from income taxes Net income Basic earnings per share Diluted earnings per share Total assets Long-term debt, net of current maturities $ $ $ $ $ $ 2020 2019 Year Ended December 31, 2018 2017 2016 2,545,626 $ 1,107,804 1,437,822 800,267 226,598 2,311,659 $ 1,054,663 1,256,996 824,625 202,710 2,289,415 $ 1,066,264 1,223,151 834,783 199,196 2,160,153 $ 972,450 1,187,703 806,790 250,157 2,068,172 929,744 1,138,428 814,697 205,708 — 21,861 1,771 — 23,416 2,245 292,513 23,962 2,861 11,506 23,014 9,128 (4,495,825) (24,488) 4,907,638 (1,101,371) 3,806,267 $ (2,030,987) (26,094) 2,261,081 (502,406) 1,758,675 $ (606,230) (36,593) 512,659 (147,045) 365,614 $ — (10,697) 97,805 24,444 122,249 $ 62,305 23,380 4,542 — (13,764) 41,560 (15,560) 26,000 127.86 $ 126.20 $ 12,972,618 $ 12,258 $ 58.93 $ 58.27 $ 8,008,859 $ 13,579 $ 12.25 $ 12.10 $ 5,611,068 $ 438,937 $ 4.12 $ 4.07 $ 4,273,012 $ 434,581 $ 0.88 0.88 3,850,504 434,186 ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion should be read in conjunction with the information contained in our consolidated financial statements and the accompanying notes which are an integral part of the statements. Overview. We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and health care specialists with products needed for clinical diagnostics. We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve. We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. Because our customers require standardization for their experiments and test results, much of our revenues are recurring. 26 We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty is the withdrawal of the United Kingdom from the European Union. Approximately 39% of our 2020 consolidated net sales are derived from the United States and approximately 61% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results. COVID-19 The full impact of the COVID-19 pandemic is inherently uncertain at the time of this report. The COVID-19 pandemic has impacted and, we expect, will continue to disrupt parts of our business operations, impacting our financial conditions and results of operations in a variety of ways. We saw strong demand for products associated with COVID-19 testing and related research, however, we saw lower demand for many of our products in the rest of our business. For more discussion relating to the impacts of the COVID-19 pandemic, please see "Item 1A, Risk Factors" to this Annual Report. Cyberattack As we previously disclosed on December 9, 2019 on a Form 8-K filed with the Securities and Exchange Commission (SEC), we detected a cyberattack on our network on the evening of December 5, 2019 PST and immediately took affected systems offline as part of our comprehensive response to contain the activity (“December 2019 Cyberattack”). The virus was targeted at Windows-based systems and did not attack our global ERP system (SAP) and other non-Windows-based systems. Critical systems were back online within a few days of the incident. As part of our in-depth investigation into this incident, we engaged outside cyber security experts to assist us with investigation and remediation efforts. We have found no evidence of unauthorized transfer or misuse of personal data, and there is no indication that customer systems were affected. We have insurance coverage for costs resulting from cyberattacks. We did not pay a ransom in connection with this incident. Acquisitions On April 1, 2020, (the "Acquisition Date") we acquired all equity interests of Celsee, Inc. ("Celsee") for total consideration of $99.3 million, including the estimated fair value of contingent consideration. The contingent consideration of up to $60.0 million is payable in cash, upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings. The acquisition was included in our Life Science segment's results of operations from the Acquisition Date. Informatics Divestiture In April 2020, we received $12.2 million for the sale of our Informatics division, which focused on providing and developing comprehensive, high-quality spectral databases and associated software. The division was part of our Other Operations segment. In connection with this sale, we recorded an $11.7 million gain in Other income, net, in the consolidated statements of income for the year ended December 31, 2020. 27 Restructurings On February 3, 2021, we initiated a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan is expected to eliminate a total of approximately 530 positions and the subsequent creation of a total of approximately 325 new positions. We anticipate the restructuring plan will be implemented in phases and is expected to be substantially completed by the end of fiscal year 2022. We estimate that as a result of this restructuring plan we will incur between approximately $125 million and $130 million in total cost, which we anticipate will consist of: (i) approximately $86 million cash expenditures in the form of one-time termination benefits to the affected employees, including cash severance payments, healthcare benefits, and related transition assistance; (ii) approximately $19 million in capital expenditures associated with the restructuring plan; and (iii) between approximately $20 million and $25 million in one-time transition costs, including employee transition costs, supply chain costs and regulatory costs. We anticipate that we will record approximately $80 million to $90 million of the charges related to this restructuring plan in the first quarter of fiscal year 2021. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional charges and future cash payments could occur in relation to the restructuring actions. Critical Accounting Policies and Estimates The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an on-going basis. We base our estimates on historical experience and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. However, future events may cause us to change our assumptions and estimates, which may require adjustment. Actual results could differ from these estimates. We have determined that for the periods reported in this Annual Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial condition and results of operations. Accounting for Income Taxes We operate in multiple jurisdictions and our profits are taxed pursuant to the tax laws of these jurisdictions. Our effective income tax rate may be affected by the changes in or interpretations of tax laws and tax agreements in any given jurisdiction, utilization of net operating loss and tax credit carryforwards, changes in geographical mix of income and expense, and changes in our assessment of matters such as the ability to realize deferred tax assets. As a result of these considerations, we must estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating current tax exposure together with assessing temporary differences resulting from the different treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in the consolidated balance sheet. We assess the likelihood that our deferred tax assets will be recovered from future taxable income, considering all available evidence such as historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax strategies. When we determine that it is not more likely than not that we will realize all or part of our deferred tax assets, an adjustment is charged to earnings in the period when such determination is made. Likewise, if we later determine that it is more likely than not that all or a part of our deferred tax assets would be realized, the previously provided valuation allowance would be reversed. 28 We make certain estimates and judgments about the application of tax laws, the expected resolution of uncertain tax positions and other matters surrounding the recognition and measurement of uncertain tax benefits. In the event that uncertain tax positions are resolved for amounts different than our estimates, or the related statutes of limitations expire without the assessment of additional income taxes, we will be required to adjust the amounts of the related assets and liabilities in the period in which such events occur. Such adjustments may have a material impact on our income tax provision and our results of operations. Business Acquisitions Accounting for business acquisitions requires us to make significant estimates and assumptions, especially at the acquisition date with respect to tangible and intangible assets acquired and liabilities assumed and pre-acquisition contingencies. In a business combination, we allocate the purchase price to the acquired business’ identifiable assets and liabilities at their acquisition date fair values. The excess of the purchase price over the amount allocated to the identifiable assets and liabilities, if any, is recorded as goodwill. To date, the assets acquired and liabilities assumed in our business combinations have primarily consisted of acquired working capital and definite-lived intangible assets. The carrying value of acquired working capital approximates its fair value, given the short-term nature of these assets and liabilities. We estimate the fair value of definite-lived intangible assets acquired using a discounted cash flow approach, which includes an analysis of the future cash flows expected to be generated by such assets and the risk associated with achieving such cash flows. The key assumptions used in the discounted cash flow model include the discount rate that is applied to the discretely forecasted future cash flows to calculate the present value of those cash flows and the estimate of future cash flows attributable to the acquired intangible assets, which include revenue, operating expenses and taxes. Our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair value of assets acquired and liabilities assumed, with the corresponding offset to goodwill. Goodwill Goodwill represents the excess of (a) the aggregate of the fair value of consideration transferred in a business combination over (b) the fair value of assets acquired, net of liabilities assumed. Goodwill is not amortized, but is subject to annual impairment tests as described below. We conduct a goodwill impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, a trend of negative or declining cash flows, a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods, or other relevant entity-specific events such as changes in management, key personnel, strategy or customers, contemplation of bankruptcy, or litigation. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested at the reporting unit level using a quantitative impairment test. For the year ended December 31, 2020, we elected to perform a qualitative assessment and determined that impairment was not more likely than not and no further analysis was required. 29 Intangible Assets We acquired intangible assets in connection with certain of our business acquisitions. These assets were recorded at their estimated fair values at the acquisition date and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. Estimated useful lives are determined based on our historical use of similar assets and the expectation of future realization of cash flows attributable to the intangible assets. Changes in circumstances, such as technological advances or changes to our business model, could result in the actual useful lives differing from our current estimates. In those cases where we determine that the useful life of an intangible asset should be shortened, we amortize the net book value in excess of the estimated salvage value over its revised remaining useful life. We did not revise our previously assigned useful life estimates attributed to any of our intangible assets during the years ended December 31, 2020, 2019 and 2018. The estimated useful lives used in computing amortization of intangible assets are as follows: Customer relationships/lists 4 – 16 years Know how 14 years Developed product technology 7 – 20 years Licenses 12 – 13 years Tradenames 10 – 15 years Covenants not to compete 3 – 10 years Impairment of Long-Lived Assets We review our long-lived assets, including property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset or an asset group may not be recoverable. Typical indicators that an asset may be impaired include, but are not limited to: • • • a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated. Recoverability measurement and estimating of undiscounted cash flows for assets to be held and used is done at the lowest possible levels for which there are identifiable cash flows. If such assets are considered impaired, generally the amount of impairment recognized would be equal to the amount by which the carrying amount of the assets exceeds the fair value of the assets, which we would compute using a discounted cash flow approach. Assets to be disposed of are recorded at the lower of the carrying amount or fair value less costs to sell. Estimating future cash flows attributable to our long-lived assets requires significant judgment and projections may vary from cash flows eventually realized. There were no triggering events to cause us to record an impairment charge for the year ended December 31, 2020. Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. 30 Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. 31 Valuation of Inventories We value inventory at the lower of the actual cost to purchase and/or manufacture the inventory, or the current estimated net realizable value of the inventory. We review inventory quantities on hand and reduce the cost basis of excess and obsolete inventory based primarily on an estimated forecast of product demand, production requirements and the quality, efficacy and potency of raw materials. This review is done at the end of each fiscal quarter. In addition, our industry is characterized by technological change, frequent new product development and product obsolescence that could result in an increase in the amount of obsolete inventory quantities on hand. Our estimates of future product demand may prove to be inaccurate, and if too high, we may have overstated the carrying value of our inventory. In the future, if inventory is determined to be overvalued, we would be required to write down the value of inventory to market and recognize such costs in our cost of goods sold at the time of such determination. Therefore, although we make efforts to ensure the accuracy of our forecasts of future product demand and perform procedures to safeguard overall inventory quality, any significant unanticipated changes in demand, technological developments, regulations, storage conditions, or other economic or environmental factors affecting biological materials, could have a significant impact on the value of our inventory and reported results of operations. Results of Operations - Sales, Gross Margins and Expenses - Incorporating by Reference the Results of Operations - Sales, Gross Margins and Expenses from our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales: Net sales Cost of goods sold Gross profit Selling, general and administrative expense Research and development expense Net income Net sales 2020 2019 100.0 % 43.5 56.5 31.4 8.9 149.5 100.0 % 45.6 54.4 35.7 8.8 76.1 Net sales (sales) for the year ended December 31, 2020 were $2.55 billion, compared to $2.31 billion for the year ended December 31, 2019, an increase of 10.1%. Excluding the impact of foreign currency, for the year ended December 31, 2020 sales increased by approximately 10.3% compared to the year ended December 31, 2019. Currency neutral sales were led by growth in Asia Pacific and Europe. The Life Science segment sales for the year ended December 31, 2020 were $1.23 billion, an increase of 39.0% compared to the year ended December 31, 2019. On a currency neutral basis, sales increased 38.6% compared to the year ended December 31, 2019. The currency neutral sales increase was primarily driven by growth in our Gene Expression, Droplet Digital PCR, and Process Media product lines. All regions reported double digit increases in currency neutral sales. Sales for the year ended December 31, 2020 benefited from product lines used in the diagnosis of COVID-19, the carryover related to the December 2019 cyberattack and a $32 million damages award related to an intellectual property litigation that pertained to sales of infringing products that occurred during fiscal years 2015 to 2018. Sales were impacted negatively in other product lines due to lab closures and reduced capacity resulting from the COVID-19 pandemic. 32 The Clinical Diagnostics segment sales for the year ended December 31, 2020 were $1.31 billion, a decrease of 7.6% compared to the year ended December 31, 2019. On a currency neutral basis, sales decreased 7.1% compared to the year ended December 31, 2019. All regions reported a currency neutral sales decline. Sales decreased across all product lines, with the exception of quality controls. Sales for the year ended December 31, 2020 benefited from the carryover related to the December 2019 cyberattack but were impacted negatively due to the effect of COVID-19 on our customers’ operations. Gross margin Consolidated gross margins were 56.5% for the year ended December 31, 2020 compared to 54.4% for the year ended December 31, 2019. Life Science segment gross margins for the year ended December 31, 2020 increased by approximately 3.1 percentage points compared to the year ended December 31, 2019, primarily due to higher sales, favorable product mix, and lower production costs, partially offset by the $7.4 million cost of sales benefit in the first quarter of 2019 from an escrow release related to an acquisition from 2011 and increased customs duty recognized during the year ended December 31, 2020 relating to products shipped primarily in prior years. Clinical Diagnostics segment gross margins for the year ended December 31, 2020 decreased slightly by approximately 0.1 percentage points compared to the year ended December 31, 2019. The lower sales for the year ended December 31, 2020 were primarily offset by lower service and support activity as a result of COVID-19 and favorable product mix. Selling, general and administrative expense Consolidated selling, general and administrative expenses (SG&A) decreased to $800.3 million or 31.4% of sales for the year ended December 31, 2020 compared to $824.6 million or 35.7% of sales for the year ended December 31, 2019. Decreases in SG&A were primarily related to lower travel costs, marketing and communication expenses of $35 million mostly due to the impact of COVID-19, partially offset by higher employee costs, and third-party professional services costs. Research and development expense Research and development (R&D) expense increased to $226.6 million or 8.9% of sales for the year ended December 31, 2020 compared to $202.7 million or 8.8% of sales for the year ended December 31, 2019. Life Science segment R&D expense increased for the year ended December 31, 2020 compared to the year ended December 31, 2019, primarily driven by increased spending to accelerate innovation in key investment areas as well as expenses related to the newly acquired Celsee business. Clinical Diagnostics segment R&D decreased for the year ended December 31, 2020 from the year ended December 31, 2019 primarily due to lower spending as a result of COVID-19 restrictions and lower headcount related to restructuring programs. Results of Operations – Non-operating Interest expense Interest expense for the years ended December 31, 2020 and 2019 was $21.9 million and $23.4 million, respectively. Foreign currency exchange gains and losses Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Net foreign currency exchange losses for the years ended December 31, 2020 and 2019 were $1.8 million and $2.2 million, respectively. The net foreign currency exchange losses were attributable to market volatility, the result of the estimating process inherent in the timing of shipments and payments of intercompany debt, and the cost of hedging. All years are affected by the economic hedging program we employ to hedge our intercompany receivables and payables denominated in foreign currencies. 33 Change in fair market value of equity securities Change in fair market value of equity securities were gains of $4.50 billion for the year ended December 31, 2020 compared to $2.03 billion for the year ended December 31, 2019, primarily resulting from the recognition of holding gains on our position in Sartorius AG. Other income, net Other income, net includes investment and dividend income, interest income on our cash and cash equivalents, short-term investments and long-term marketable securities. Other income, net for the year ended December 31, 2020 decreased to $24.5 million compared to $26.1 million for the year ended December 31, 2019. Other income, net decreased primarily due to lower investment income of $6.0 million and lower Sartorius AG dividend income of $6.8 million, partially offset by the gain on the sale of the Informatics division of $11.7 million for the year ended December 31, 2020. Effective tax rate Our effective tax rates were 22.4% and 22.2% for the years ended December 31, 2020 and 2019, respectively. The effective tax rates for the years ended December 31, 2020 and 2019 were driven by the unrealized gain in equity securities that is taxed at approximately 22% as well as the geographic mix of earnings and the taxation of our foreign earnings. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes in the geographic mix of earnings, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits. Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. As of December 31, 2020, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $17.2 million. Substantially all such amounts will impact our effective income tax rate. Comparison of the Year Ended December 31, 2019 to the Year Ended December 31, 2018 Refer to Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations located in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed on March 2, 2020, for the discussion of the comparison of the fiscal year ended December 31, 2019 to the fiscal year ended December 31, 2018, the earliest of the three fiscal years presented in the Consolidated Statements of Operations. 34 Liquidity and Capital Resources Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade. Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world. Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price. Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows for capital expenditures, interest and taxes. In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured revolving credit facility (Credit Agreement) that we entered into in April 2019, and to a lesser extent international lines of credit. Borrowings under the Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2020; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and acquisitions of reasonable proportion to our existing total available capital. In December 2020, we paid in full the $425.0 million principal amount of Senior Notes, including accrued interest. Because the Company might be deemed an investment company under the Investment Company Act based on the market value of our position in Sartorius AG, the Company may not be able to access the capital markets or otherwise obtain additional financing until it is determined that the Company is not an investment company. The inability to obtain additional financing may have a negative impact on the Company's ability to make acquisitions or other non-routine investments. At December 31, 2020, we had available $991.1 million in cash, cash equivalents and short-term investments, of which approximately 37% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as acquisitions. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows). It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. Demand for our products and services could change more dramatically in the short-term than in previous years due to the impacts of the COVID-19 pandemic, as well as due to funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories. The need for certain sovereign nations with large annual deficits to curtail spending, international trade disputes and increased regulation, could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity. 35 Cash Flows from Operations Net cash provided by operations was $575.3 million and $457.9 million for the years ended December 31, 2020 and 2019, respectively. The net increase between the year ended December 31, 2020 and the year ended December 31, 2019 of $117.4 million was primarily due to higher cash received from customers as a result of the growth in sales for product lines used for COVID-19. These increases were partially offset by higher cash paid to suppliers primarily for supplies associated with COVID-19 products, and cash paid for employee related expenses such as salaries and benefits, and to a lesser extent for employee restructuring programs. The decrease also consisted of higher income taxes paid and lower investment income. Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth quarter sales commissions to third parties and annual employee bonuses, and we expect this pattern to recur in the first quarter of 2021. Cash Flows from Investing Activities Our investing activities have consisted primarily of cash used for acquisitions, capital expenditures and activity related to the purchases, sales and maturities of marketable securities. Net cash used in investing activities was $60.3 million and $208.9 million for the years ended December 31, 2020 and 2019, respectively. The decrease of $148.6 million was primarily attributable to a $159.5 million increase in net proceeds from maturities, sales and purchases of marketable securities and proceeds from a divestiture of $12.2 million, partially offset by a $17.3 million increase in payments for acquisitions. Cash Flows from Financing Activities Our financing activities have consisted primarily of cash used for purchases of treasury stock, taxes paid on the vesting of restricted stock units and proceeds from the issuance of common stock for share-based compensation. Net cash used in financing activities was $523.0 million compared to $22.8 million for the years ended December 31, 2020 and 2019, respectively. This increase was primarily attributable to the repayment of the $425 million principal amount of Senior Notes, and $72.0 million to purchase treasury stock. Treasury Shares During the year ended December 31, 2020, 117,423 shares of Class A treasury stock with an aggregate total cost of $38.5 million were reissued to fulfill grants to employees under our restricted stock program. Upon reissuing the Class A treasury stock, a loss of $9.0 million was incurred as they were reissued at a lower price than their average cost, which reduced Retained earnings, while $29.5 million reduced Additional paid-in capital. During the year ended December 31, 2019, 117,993 shares of Class A treasury stock with an aggregate total cost of $33.2 million were reissued to fulfill grants to employees under our restricted stock program. Upon reissuing the Class A treasury stock, a loss of $8.4 million was incurred as they were reissued at a lower price than their average cost, which reduced Retained earnings, while $24.9 million reduced Additional paid-in capital. The re-issuance of the treasury stock for the years ended December 31, 2020 and 2019 did not require cash payments or receipts and therefore did not affect liquidity. During the year ended December 31, 2020, we repurchased 291,941 shares of Class A common stock for $100.0 million under our repurchase program, compared to the repurchase of 88,486 shares of our common stock for $28.0 million during the year ended December 31, 2019. We designated these repurchased shares as treasury stock. 36 During the year ended December 31, 2019, 19,755 shares of Class A treasury stock with an aggregate total cost of $5.4 million were reissued to fulfill our Employee Stock Purchase Plan purchases. A loss of $1.6 million was incurred upon reissuing the Class A treasury stock as they were reissued at a lower price than their average cost, which reduced Retained earnings and resulted in net proceeds of $3.8 million. In November 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock (“Share Repurchase Program”). In July 2020, the Board of Directors authorized increasing the Share Repurchase Program to allow the Company to repurchase up to an additional $200.0 million of stock. As of December 31, 2020, $273.1 million remained under the Share Repurchase Program. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements that have had or are reasonably likely to have a current or future material effect on our financial condition, results of operations or liquidity. Contractual Obligations The following summarizes certain of our contractual obligations as of December 31, 2020 and the effect such obligations are expected to have on our cash flows in future periods (in millions): Contractual Obligations Long-term debt, including current portion (1) Interest payments (1) Operating lease obligations (2) Purchase obligations (3) Long-term liabilities (4) $ $ $ $ $ Payments Due by Period Less Than One Year Total 1-3 Years 3-5 Years More than 5 Years 14.1 $ 8.6 $ 252.9 $ 16.6 $ 134.0 $ 1.8 $ 0.9 $ 43.6 $ 14.1 $ 2.7 $ 2.2 $ 1.5 $ 68.3 $ 2.3 $ 19.3 $ 0.8 $ 1.4 $ 50.4 $ 0.2 $ 9.4 $ 9.3 4.8 90.6 — 102.6 (1) These amounts represent expected cash payments, primarily from finance lease obligations, which are included in our December 31, 2020 consolidated balance sheet. See Note 5 of the consolidated financial statements for additional information about our debt. (2) Operating lease obligations are described in Note 16 of the consolidated financial statements. (3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms. Purchase obligations exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad. (4) These amounts primarily represent recognized long-term obligations for other post-employment benefits mostly due in more than 5 years, and long-term deferred revenue. Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $65.5 million. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table above. See Note 6 of the consolidated financial statements for additional information about our income taxes. Recent Accounting Pronouncements Adopted and to be Adopted See Note 1 to the consolidated financial statements for recent accounting pronouncements adopted and to be adopted. 37 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Financial Risk Management The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows arising from unexpected foreign exchange rate and interest rate changes. Financial exposures are managed through operational means and by using various financial instruments, including cash and liquid resources, borrowings, and forward and spot foreign exchange contracts. No derivative financial instruments are entered into for the purpose of trading or speculation. Company policy requires that all derivative positions are undertaken to manage the risks arising from underlying business activities. These derivative transactions do not qualify for hedge accounting treatment. Derivative instruments used in these transactions are valued at fair value and changes in fair value are included in reported earnings. Foreign Exchange Risk. We operate and conduct business in many countries and are exposed to movements in foreign currency exchange rates. We face transactional currency exposures that arise when we enter into transactions denominated in currencies other than U.S. dollars. Additionally, our consolidated net equity is impacted by the conversion of the net assets of our international subsidiaries for which the functional currency is not the U.S. dollar. Foreign currency exposures are managed on a centralized basis. This allows for the netting of natural offsets and lowers transaction costs and net exposures. Where possible, we seek to manage our foreign exchange risk in part through operational means, including matching same-currency revenues to same-currency costs, and same-currency assets to same-currency liabilities. Moreover, weakening in one currency can often be offset by strengthening in another currency. Foreign exchange risk is also managed through the use of forward foreign exchange contracts. Positions are primarily in Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. The majority of forward contracts are for periods of 90 days or less. We record the change in value of our foreign currency receivables and payables as a Foreign exchange (gain) loss on our Consolidated Statements of Income along with the change in fair market value of the forward exchange contract used as an economic hedge of those assets or liabilities. Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign currency exchange rates. All other variables were held constant. Market risk associated with derivative holdings is the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange rates. A decline of 10% on quoted foreign exchange rates would result in an approximate net-present-value loss of $18 million on our derivative position as of December 31, 2020. This impact of a change in exchange rates excludes the offset derived from the change in value of the underlying assets and liabilities, which could reduce the adverse effect significantly. Interest Rate Risk of Debt Instruments. Bio-Rad centrally manages the short-term cash surpluses and shortfalls of its subsidiaries. Our holdings of variable rate debt instruments at year-end were analyzed to determine their sensitivity to movements in interest rates. Due to the relatively small amount of short-term variable rate debt instruments we have outstanding, there would not be a material impact to earnings or cash flows if interest rates moved adversely by 10%. Our holdings of long-term debt instruments consist primarily of fixed-rate instruments and are thus insulated from interest rate changes. As of December 31, 2020, the overall interest rate risk associated with our debt instruments was not significant. 38 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Consolidated Financial Statements Reports of Independent Registered Public Accounting Firm Consolidated Balance Sheets at December 31, 2020 and 2019 Consolidated Statements of Income for each of the three years in the period ended December 31, 2020 Consolidated Statements of Comprehensive Income for each of the three years in the period December 31, 2020 Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2020 Consolidated Statements of Changes in Stockholders’ Equity for each of the three years in the period ended December 31, 2020 Notes to Consolidated Financial Statements Page 40-42 43-44 45 46 47 48 49-90 39 Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors Bio-Rad Laboratories, Inc.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, changes in stockholders’ equity, and cash flows for each of the years in the three‑year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three- year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 12, 2021 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting. Changes in Accounting Principle As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases effective January 1, 2019 due to the adoption of Accounting Standard Update (ASU) 2016-02, Leases, and related accounting standard updates. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. 40 Assessment of Lease Term for Reagent Rental Arrangements As discussed in Note 1 to the consolidated financial statements, the Company earns revenue from reagent rental agreements with its customers. Each agreement generally includes lease elements subject to the lease accounting standards and non-lease elements subject to the revenue accounting standards. The classification of the lease component as an operating or sales-type lease can impact the timing of revenue recognition and cost attributable to the underlying lease elements. While most reagent rental arrangements contain an option for a lessee to extend and the option for the lessee to cancel or both, the period in which the contract is enforceable is generally short, and the lease term has been determined to generally be the noncancelable period. The revenue allocated to the reagent rental lease elements was approximately 3% of total revenue for the year ended December 31, 2020 and it is included as part of Net Sales in the Consolidated Statement of Income. We identified the assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, as a critical audit matter. The Company’s determination of lease classification as operating or sales-type lease is primarily dependent on the initial determination of the lease term. The Company’s process is based on the manual examination of a high volume of agreements that are negotiated individually across the world with diverse terms. Testing the determination of the lease term, including consideration of contractual termination penalties, required a high degree of auditor judgment to design and execute the audit procedures. The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s lease classification process. This included controls related to the Company’s process for determining the lease term including consideration of contractual termination penalties. We assessed the Company’s policy for determining that the lease term of its reagent rental arrangements was in accordance with U.S generally accepted accounting principles. Additionally, for a selection of reagent rental agreements, we read the underlying contract, and compared relevant terms within the contract to the Company’s determination of lease term analysis and evaluated management’s judgment on the determination of the length of the lease term. We evaluated the sufficiency of the evidence obtained by assessing the results of procedures performed, including the appropriateness of the nature and extent of such evidence. /s/ KPMG LLP We have served as the Company's auditor since 2013. Santa Clara, California February 12, 2021 41 Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors Bio‑Rad Laboratories, Inc.: Opinion on Internal Control Over Financial Reporting We have audited Bio-Rad Laboratories, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for each of the years in the three- year period ended December 31, 2020, (collectively, the consolidated financial statements), and our report dated February 12, 2021 expressed an unqualified opinion on those consolidated financial statements. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control Over Financial Reporting A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Santa Clara, California February 12, 2021 /s/ KPMG LLP 42 BIO-RAD LABORATORIES, INC. Consolidated Balance Sheets (In thousands, except share data) ASSETS Current assets: Cash and cash equivalents Short-term investments Restricted investments Accounts receivable, less allowance for doubtful accounts of $19,807 and $20,205 as of December 31, 2020 and 2019, respectively $ 662,205 $ 328,913 5,560 660,672 453,973 5,560 419,424 392,672 December 31, 2020 2019 Inventories: Raw materials Work in process Finished goods Total inventories Prepaid expenses Other current assets Total current assets Property, plant and equipment: Land and improvements Buildings and leasehold improvements Equipment Total property, plant and equipment Less: accumulated depreciation and amortization Property, plant and equipment, net Operating lease right-of-use assets Goodwill, net Purchased intangibles, net Other investments Other assets Total assets 126,911 151,931 343,411 622,253 109,570 146,131 298,306 554,007 90,621 10,859 2,139,835 102,331 10,940 2,180,155 25,739 363,048 1,063,974 1,452,761 (961,390) 491,371 25,215 341,598 1,015,359 1,382,172 (882,833) 499,339 202,136 291,916 199,497 9,561,140 86,723 201,868 264,131 145,525 4,638,205 79,636 $ 12,972,618 $ 8,008,859 The accompanying notes are an integral part of these consolidated financial statements. 43 BIO-RAD LABORATORIES, INC. Consolidated Balance Sheets (continued) (In thousands, except share data) LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued payroll and employee benefits Current maturities of long-term debt Income taxes payable Other taxes payable Current operating lease liabilities Deferred revenue Other current liabilities Total current liabilities Long-term debt, net of current maturities Deferred income taxes Operating lease liabilities Other long-term liabilities Total liabilities Commitments and contingent liabilities Stockholders’ equity: Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,072,619 and 24,966,035 at 2020 and 2019, respectively; shares outstanding - 24,767,870 and 24,835,804 at 2020 and 2019, respectively Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,076,186 and 5,089,532 at 2020 and 2019, respectively Additional paid-in capital Class A treasury stock at cost, 304,749 shares at 2020 and 130,231 shares at 2019 Retained earnings Accumulated other comprehensive income (loss) Total stockholders’ equity Total liabilities and stockholders’ equity December 31, 2020 2019 $ 139,451 $ 222,875 1,798 23,282 34,053 36,507 42,468 131,102 631,536 107,014 180,084 426,172 8,763 27,522 35,365 33,735 86,840 905,495 12,258 2,076,785 175,128 196,971 3,092,678 13,579 997,787 176,018 160,923 2,253,802 — 2 — 2 1 429,376 (99,907) 1 410,020 (38,397) 5,470,779 (87,348) 5,755,057 $ 12,972,618 $ 8,008,859 9,268,012 282,456 9,879,940 The accompanying notes are an integral part of these consolidated financial statements. 44 BIO-RAD LABORATORIES, INC. Consolidated Statements of Income (In thousands, except per share data) Net sales Cost of goods sold Gross profit Selling, general and administrative expense Research and development expense Impairment losses on goodwill and long-lived assets Income (loss) from operations Interest expense Foreign currency exchange losses, net Change in fair market value of equity securities Other income, net Income before income taxes Provision for income taxes Net income Basic earnings per share: Net income per basic share Weighted average common shares - basic Diluted earnings per share: Net income per diluted share Weighted average common shares - diluted $ $ $ $ Year Ended December 31, 2020 2019 2018 2,545,626 $ 1,107,804 1,437,822 800,267 226,598 — 410,957 21,861 1,771 (4,495,825) (24,488) 4,907,638 (1,101,371) 3,806,267 $ 2,311,659 $ 1,054,663 1,256,996 824,625 202,710 — 229,661 23,416 2,245 (2,030,987) (26,094) 2,261,081 (502,406) 1,758,675 $ 2,289,415 1,066,264 1,223,151 834,783 199,196 292,513 (103,341) 23,962 2,861 (606,230) (36,593) 512,659 (147,045) 365,614 127.86 $ 29,768 58.93 $ 29,843 12.25 29,836 126.20 $ 30,160 58.27 $ 30,184 12.10 30,228 The accompanying notes are an integral part of these consolidated financial statements. 45 BIO-RAD LABORATORIES, INC. Consolidated Statements of Comprehensive Income (In thousands) Net income Other comprehensive income (loss), net of tax: Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale (AFS) investments Other comprehensive income (loss), net of tax Comprehensive income Year Ended December 31, 2019 2020 $ 3,806,267 $ 1,758,675 $ 2018 365,614 371,057 (3,806) (36,953) (7,363) (112,857) 7,549 2,553 369,804 3,926 (40,390) $ 4,176,071 $ 1,718,285 $ (1,187) (106,495) 259,119 The accompanying notes are an integral part of these consolidated financial statements. 46 BIO-RAD LABORATORIES, INC. Consolidated Statements of Cash Flows (In thousands) Year Ended December 31, 2019 2020 2018 Cash flows from operating activities: Cash received from customers Cash paid to suppliers and employees Interest paid, net Income tax payments, net Investment proceeds and miscellaneous receipts, net (Payments for) proceeds from forward foreign exchange contracts, net Net cash provided by operating activities Cash flows from investing activities: Capital expenditures Proceeds from dispositions of property, plant and equipment Proceeds from divestiture of a division (Payments for) proceeds from acquisitions, net of cash received Recovery of (payments for) purchases of intangible assets Payments for purchases of marketable securities and investments Proceeds from sales of marketable securities and investments Proceeds from maturities of marketable securities and investments Net cash used in investing activities Cash flows from financing activities: Payments on long-term borrowings Payments for credit agreement renewal fees Proceeds from issuances of common stock for share-based compensation Tax payments from net share settlement Proceeds from reissuances of treasury stock for shared-based compensation, net Payments for purchases of treasury stock Payments of contingent consideration Net cash used in financing activities Effect of foreign exchange rate changes on cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of year Cash, cash equivalents and restricted cash at end of year $ 2,531,135 $ 2,311,925 $ 2,326,310 (1,886,988) (1,818,575) (1,989,685) (22,703) (62,414) 26,383 7,603 285,494 (22,330) (45,081) 31,673 285 457,897 (21,639) (65,244) 21,488 (3,424) 575,328 (98,920) 70 12,240 (96,655) 3,414 (248,457) 89,734 278,324 (60,250) (98,532) 129 — (79,386) 8,818 (371,450) 104,632 226,900 (208,889) (129,825) 4,315 6,964 266 (3) (371,019) 77,029 225,295 (186,978) (426,938) — (643) (486) (2,961) — 20,198 (12,930) 13,113 (8,096) 14,133 (8,862) — — (48,912) (2,078) (48,680) (655) 49,181 384,983 $ 667,115 $ 662,651 $ 434,164 3,831 (28,000) (2,477) (22,758) 2,237 228,487 434,164 (100,004) (3,367) (523,041) 12,427 4,464 662,651 The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that agrees to the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, Cash and cash equivalents Restricted cash included in Other current assets Restricted cash included in Other assets Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows 2020 2019 $ 662,205 $ 660,672 $ 431,526 111 2,527 93 1,886 3,994 916 2018 $ 667,115 $ 662,651 $ 434,164 These restricted cash items are primarily related to performance guarantees and other restricted deposits. The accompanying notes are an integral part of these consolidated financial statements. 47 BIO-RAD LABORATORIES, INC. Consolidated Statements of Changes in Stockholders’ Equity (In thousands) Balance at December 31, 2017 Effect of adoption of ASU 2016-01 and ASU 2018-03* Effect of adoption of ASU 2016-16** Effect of adoption of ASC 606*** Net income Other comprehensive loss, net of tax Issuance of common stock Stock compensation expense Purchase of treasury stock Balance at December 31, 2018 Net income Other comprehensive loss, net of tax Issuance of common stock Stock compensation expense Purchase of treasury stock Reissuance of treasury stock Balance at December 31, 2019 Net income Other comprehensive income, net of tax Issuance of common stock Stock compensation expense Purchase of treasury stock Reissuance of treasury stock Common Stock Additional Paid- in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income Total Stockholders' Equity $ 3 $ 361,231 $ (217) $ 1,830,439 $ 738,794 $ 2,930,250 — — — — — — — — 3 — — — — — — 3 — — — — — — — — — — — 5,271 27,840 — 394,342 — — 5,017 35,593 — (24,932) 410,020 — — 7,268 41,556 — (29,468) — 1,543,747 (679,257) 864,490 — — — (17,591) (136) 365,614 — — — (17,591) (136) 365,614 — — — — — — — (48,912) (49,129) 3,722,073 1,758,675 — (106,495) — — — (106,495) 5,271 27,840 (48,912) (46,958) 4,020,331 1,758,675 — — — — (28,000) — — — — (40,390) — — — (40,390) 5,017 35,593 (28,000) (9,969) 38,732 (38,397) 5,470,779 3,806,267 — — 3,831 (87,348) 5,755,057 3,806,267 — — — — (100,004) 38,494 — — — — (9,034) 369,804 — — — — 369,804 7,268 41,556 (100,004) (8) Balance at December 31, 2020 $ 3 $ 429,376 $ (99,907) $ 9,268,012 $ 282,456 $ 9,879,940 * ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities, and ASU 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities," as disclosed in our December 31, 2018 Form 10-K ** ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," as disclosed in our December 31, 2018 Form 10-K *** See Note 1, "Significant Accounting Policies" under "Revenue Recognition." The accompanying notes are an integral part of these consolidated financial statements. 48 BIO-RAD LABORATORIES, INC. Notes to Consolidated Financial Statements 1. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash. Cash equivalents are stated at cost, which approximates fair value. Short-term Restricted Investments Short-term restricted investments of $5.6 million at both December 31, 2020 and 2019 represent a money market fund that is provided as collateral to secure worker's compensation and general liability insurance. Available-for-Sale Investments Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities and U.S. government sponsored agencies. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect. On January 1, 2020, we adopted Accounting Standards Update (ASU) 2016-13 described below under "Recent Accounting Pronouncements Adopted." In accordance with the adopted guidance, we replaced the incurred loss approach with an expected loss model for instruments measured at amortized cost and we record allowances for available-for-sale debt securities rather than to reduce the carrying amount for other-than-temporary impairment as was followed under the other-than-temporary impairment model prior to January 1, 2020. Realized gains and losses and other-than-temporary impairments on investments are included in Other income and expense, net (see Note 10). 49 Concentration of Credit Risk Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable. Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end. Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas. We manage our accounts receivable credit risk through ongoing credit evaluation of our customers' financial conditions. We generally do not require collateral from our customers. Accounts Receivable and Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. On January 1, 2020 we adopted ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" as described below and review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Prior to January 1, 2020, the allowance for doubtful accounts was determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers' country or industry, historical losses and our customers' credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of the customer. Changes in our allowance for doubtful accounts were as follows (in millions): December 31, Beginning balance Provision for expected credit losses (2020), bad debt (reversal) expense (2019 and 2018) Write-offs charged against the allowance Recoveries collected Ending balance Inventory 2020 2019 2018 $ 20.2 $ 26.7 $ 25.5 1.2 (1.6) — 19.8 $ (1.2) (6.6) 1.3 20.2 $ 3.9 (2.7) — 26.7 $ Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. Cost is determined using standard costs, which approximate actual costs, and are relieved from inventory on a first- in, first-out or average cost basis. We classify our inventories based on our historical and anticipated levels of sales; any inventory in excess of its normal operating cycle (1 – 3 years depending on our product line) is classified as long-term on our consolidated balance sheets. The long-term inventory was immaterial as of December 31, 2020 and 2019. 50 Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Additions and improvements are capitalized, and maintenance and repairs are expensed as incurred. Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are generally as follows: buildings, 10-50 years; leasehold improvements, the life of the improvements or the term of the lease, whichever is shorter; reagent rental equipment, 1-5 years; and equipment, 3-12 years. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are relieved from the accounts and the net gain or loss is included in operating expenses. Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of- use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements." Intangible Assets Our intangible assets principally include goodwill, acquired technology / know how, license, tradenames and customer relationships. Intangible assets with finite lives, which include acquired technology / know how, tradenames, licenses and customer relationships, are carried at cost and amortized using the straight-line method over their useful lives ranging from 3 to 20 years. Intangible assets with indefinite lives, which include only goodwill, are recorded at cost and evaluated at least annually for impairment. 51 Impairment of Long-Lived Assets We review long-lived assets, such as property, plant and equipment, and finite-lived intangible assets, for impairment whenever events indicate that the carrying amounts might not be recoverable. Recoverability of property, plant and equipment, and other finite-lived intangible asset is measured by comparing the projected undiscounted net cash flows associated with those assets to their carrying values. If an asset is considered impaired, it is written down to its fair value, which is determined based on the asset's projected discounted cash flows or appraised value, depending on the nature of the asset. For purposes of recognition of impairment for assets held for use, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. For the year ended December 31, 2018, we impaired some finite-lived intangible assets in the amount of $10.5 million that were included in our Life Science segment's results of operations. There were no impairments of finite- lived intangible assets for the years ended December 31, 2020 and 2019. Impairment of Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct a goodwill impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. In reviewing goodwill for impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (greater than 50%) that the estimated fair value of a reporting unit is less than its carrying amount. For the year ended December 31, 2020, we elected to perform a qualitative assessment and determined that an impairment was not more likely than not and no further analysis was required. We also may elect not to perform the qualitative assessment and, instead, proceed directly to the quantitative impairment test. The ultimate outcome of the goodwill impairment review for a reporting unit should be the same whether we choose to perform the qualitative assessment or proceed directly to the quantitative impairment test. For the year ended December 31, 2018, we impaired goodwill in the amount of $282.0 million, which was included in our Clinical Diagnostics and our Life Science segments' results of operations in the amounts of $276.1 million and $5.9 million, respectively. There was no impairment of goodwill for the years ended December 31, 2020 and 2019. Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. 52 When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million. Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. 53 Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. In the fourth quarter of fiscal year 2020, we received $35.3 million in court awarded damages related to an intellectual property litigation for sales of products infringing on our patents during 2015 to 2018. Of the total amount, we recognized $32.3 million as revenue upon receipt of the damages based on the estimated stand-alone royalty rate associated with the infringed patents. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non- lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in accordance with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in Net sales in our consolidated statements of income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. 54 Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales- type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 3% of total revenue at both December 31, 2020 and 2019, respectively, and 5% at December 31, 2018, and are included as part of the Net sales in our consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our consolidated statements of income. Disaggregation of Revenue: The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14). Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at December 31, 2020 and December 31, 2019 was $60.0 million and $45.8 million, respectively. The short-term deferred revenue balance at December 31, 2020 and December 31, 2019 was $42.5 million and $33.7 million, respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets. Change in our warranty liability were as follows (in millions): January 1 Provision for warranty Actual warranty costs December 31 Shipping and Handling 2020 2019 2018 $ $ 9.0 $ 9.4 (8.6) 9.8 $ 10.1 $ 9.9 (11.0) 9.0 $ 18.7 25.5 (34.1) 10.1 We classify all freight costs billed to customers as Net sales. Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold. Research and Development All research and development costs are expensed as incurred. Types of expense incurred in research and development include materials and supplies, employee compensation, consulting and third-party services, depreciation, facility costs and information technology. 55 Foreign Currency Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. Forward Foreign Exchange Contracts As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income. Share-Based Compensation Plans Share-based compensation expense for all share-based payment awards granted is determined based on the grant- date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards. Forfeitures are recognized as they occur. These plans are described more fully in Note 9. Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Basic weighted average shares outstanding Effect of potentially dilutive stock options and restricted stock awards Diluted weighted average common shares Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS Year Ended December 31, 2019 2020 2018 29,768 29,843 29,836 392 30,160 341 30,184 392 30,228 44 98 84 56 Fair Value of Financial Instruments For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value. The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3). Equity Investments Investments in publicly traded companies in which we do not have the ability to exercise significant influence are reported at fair value, with unrealized gains and losses reported as a component of change in fair market value of equity securities in our consolidated statements of income. Companies in which we do not have a controlling financial interest, but over which we have significant influence, are accounted for using the equity method. Our share of the after-tax earnings of equity method investees is included in other income, net in our consolidated statements of income. Investments in privately held companies in which we do not have the ability to exercise significant influence are accounted for using the cost method with adjustments for observable changes in price or impairments (see Note 3). Recent Accounting Pronouncements Adopted In March 2020, the FASB issued ASU No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)." The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements," which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard effective January 1, 2020, which did not have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 was effective for fiscal years ending after December 15, 2020. We adopted the standard using a retrospective approach, which did not have a material impact to our disclosures for defined benefit plans. 57 In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. We adopted ASU 2016-13 as of January 1, 2020 using the cumulative effect transition method. We have evaluated our impacted instruments for credit quality indicators, and have determined that there is no cumulative effect transition adjustment to retained earnings as of our adoption date. ASU 2016-13 had an insignificant impact to our consolidated financial statements for 2020. See also Note 3, Fair Value Measurements, and the section above under the caption “Accounts Receivable and Allowance for Doubtful Accounts.” In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements." Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments— Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020. We do not expect ASU 2020-01 to have a material impact to our consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 is not expected to have a material impact on the consolidated financial statements. 58 2. ACQUISITIONS AND DIVESTITURES ACQUISITIONS Celsee Acquisition: On April 1, 2020 (the "Acquisition Date"), we acquired all equity interests of Celsee, Inc. ("Celsee") for total consideration of $99.3 million (as described in the table below), including the estimated fair value of contingent consideration. The contingent consideration of up to $60.0 million is payable in cash, upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings. The acquisition was included in our Life Science segment's results of operations from the Acquisition Date. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Celsee met the definition of a business, and therefore is accounted for as a business combination. The fair value of consideration transferred for the Celsee acquisition consists of the following (in millions): Purchase price (cash) Fair value of contingent consideration (earn-out) Fair value of total consideration transferred $ $ 99.2 0.1 99.3 The following table summarizes the final fair values of the assets acquired and liabilities assumed at the Acquisition Date (in millions): Cash and cash equivalents Intangible assets Deferred tax assets Deferred tax liabilities Other identifiable assets acquired, net Net identifiable assets acquired Goodwill Net assets acquired Fair Value 0.6 79.9 8.4 (19.7) 0.3 69.5 29.8 99.3 $ $ Goodwill related to the acquisition is primarily attributable to opportunities and economies of scale from combining the operations and technologies of Bio-Rad and Celsee, and is not deductible for tax purposes. The following table summarizes the final fair values and estimated useful lives of the components of identifiable intangible assets acquired as of the Acquisition Date (in millions): 59 Developed product technology Customer relationships Covenants not to compete In-process research and development Total identifiable intangible assets acquired Fair Value Estimated Useful Life (years) $ $ 70.3 3.6 1.4 4.6 79.9 18.9 4.0 3.0 Intangible assets acquired as a result of the Celsee acquisition are being amortized over their estimated useful lives using the straight-line method of amortization, which materially approximates the distribution of the economic value of the identified intangible assets. Amortization of acquired developed technology of $2.8 million for the year ended December 31, 2020 is included in Cost of goods sold in the consolidated statements of income. Amortization of the acquired customer relationships of $0.7 million and covenants not to compete of $0.4 million for the year ended December 31, 2020 are included in Selling, general and administrative expense in the consolidated statements of income. In-process research and development (IPR&D) is accounted for as an indefinite-lived asset. Once the project is completed, the carrying value of the IPR&D will be amortized over the estimated useful life of the asset. IPR&D is assessed for impairment on an annual basis until the project is completed. We believe the values of acquired intangible assets reported above represent their fair values and approximate the amounts a market participant would pay for these intangible assets as of the Acquisition Date. We included Celsee's fair value of assets acquired and liabilities assumed in our consolidated balance sheets beginning on the Acquisition Date. The results of operations for Celsee subsequent to the Acquisition Date have been included in, but are immaterial to, our consolidated statements of income for the year ended. Pro forma results of operations for the Celsee acquisition have not been presented because they are not material to the condensed consolidated statements of income. Distributor Acquisition: In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $3.4 million to customer relationships; a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets. The final allocation of payments was unchanged from our preliminary allocation for the period ended December 31, 2019. 60 Exact Diagnostics, LLC Acquisition: In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations. U.S. private company Acquisition: In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles. During the year ended December 31, 2020, goodwill was decreased by $2.0 million due to the release from an escrow account setup during our acquisition, which should have been classified as a prepaid asset in its opening balance sheet as of acquisition date. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations. DIVESTITURE Informatics Divestiture: In April 2020, we received $12.2 million for the sale of our Informatics division, which focused on providing and developing comprehensive, high-quality spectral databases and associated software. The division was part of our Other Operations segment. In connection with this sale, we recorded an $11.7 million gain in Other income, net, in the consolidated statements of income for the year ended December 31, 2020. 61 3. FAIR VALUE MEASUREMENTS AND INVESTMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • • • Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper Time deposits Asset-backed securities U.S. government sponsored agencies Money market funds Total cash equivalents (a) Restricted investments (b) Equity Securities (c) Available-for-sale investments: Corporate debt securities U.S. government sponsored agencies Foreign government obligations Other foreign obligations Municipal obligations Asset-backed securities Total available-for-sale investments (d) Forward foreign exchange contracts (e) Total financial assets carried at fair value Financial liabilities carried at fair value: Forward foreign exchange contracts (f) Contingent consideration (g) Total financial liabilities carried at fair value $ $ $ $ — $ 17.6 — — 60.1 77.7 6.7 9,582.4 — — — — — — — — 9,666.8 $ 41.7 $ 10.0 0.9 2.5 — 55.1 — — 133.2 76.9 4.0 2.1 15.2 36.2 267.6 1.0 323.7 $ — $ — — — — — — — — — — — — — — — — $ 41.7 27.6 0.9 2.5 60.1 132.8 6.7 9,582.4 133.2 76.9 4.0 2.1 15.2 36.2 267.6 1.0 9,990.5 — $ — — $ 1.0 $ — 1.0 $ — $ 0.7 0.7 $ 1.0 0.7 1.7 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): 62 Financial assets carried at fair value: Cash equivalents: Commercial paper Time deposits Asset-backed securities Money market funds Total cash equivalents (a) Restricted investments (b) Equity securities (c) Available-for-sale investments: Corporate debt securities U.S. government sponsored agencies Foreign government obligations Other foreign obligations Municipal obligations Asset-backed securities Total available-for-sale investments (d) Forward foreign exchange contracts (e) Total financial assets carried at fair value Financial liabilities carried at fair value: Forward foreign exchange contracts (f) Contingent consideration (g) Total financial liabilities carried at fair value Level 1 Level 2 Level 3 Total $ — $ 31.2 — 69.9 101.1 5.6 4,664.4 — — — — — — — — $ 4,771.1 $ 42.9 $ 10.0 0.1 — 53.0 — — 204.5 106.1 4.7 3.1 11.6 72.9 402.9 0.9 456.8 $ — $ — — — — — — 42.9 41.2 0.1 69.9 154.1 5.6 4,664.4 — — — 204.5 106.1 4.7 3.1 — 11.6 — 72.9 — 402.9 — — 0.9 — $ 5,227.9 $ $ — $ — — $ 1.0 $ — 1.0 $ — $ 4.9 4.9 $ 1.0 4.9 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the consolidated balance sheets. (b) Restricted investments are included in the following accounts in the consolidated balance sheets (in millions): Restricted investments Other investments Total December 31, 2020 December 31, 2019 $ $ 5.6 1.1 6.7 $ $ 5.6 — 5.6 (c) Equity securities are included in the following accounts in the consolidated balance sheets (in millions): Short-term investments Other investments Total December 31, 2020 December 31, 2019 $ $ 61.4 9,521.0 9,582.4 $ $ 51.0 4,613.4 4,664.4 The change in fair market value on our equity securities for the year ended December 31, 2020 was $4,495.8 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our consolidated statements of income. 63 As of December 31, 2020, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We did not purchase any incremental shares for the years ended December 31, 2020 and 2019. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of December 31, 2020. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (d) Available-for-sale investments are included in the following accounts in the consolidated balance sheets (in millions): Short-term investments Other investments Total December 31, 2020 December 31, 2019 $ $ 267.5 0.1 267.6 $ $ 402.8 0.1 402.9 (e) Forward foreign exchange contracts in an asset position are included in other current assets in the consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the consolidated balance sheets. (g) Contingent consideration liabilities are included in the following accounts in the consolidated balance sheets (in millions): Other current liabilities Other long-term liabilities Total December 31, 2020 December 31, 2019 $ $ 0.6 0.1 0.7 $ $ 3.3 1.6 4.9 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. We paid $3.3 million of sales milestone payments per the purchase agreement in 2020. All sales milestones have been fulfilled and the contingent consideration liability was accrued at its estimated fair value of $0 as of December 31, 2020. During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is currently due and is anticipated to be paid in the first half of 2021. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of December 31, 2020. 64 During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The fair value of the earn-out was approximately $0.1 million as of December 31, 2020. The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 Analytical flow cytometer platform: Payment of sales milestone Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense $ 4.9 Foreign distributor earn-outs: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense Celsee, Inc.: Fair value of contingent consideration December 31, 2020 $ (3.3) (1.0) — 0.1 0.7 To estimate the fair value of Level 2 debt securities as of December 31, 2020 and 2019, our primary pricing provider used Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Allowances for Credit Losses Estimated Fair Value Short-term investments: Corporate debt securities Municipal obligations Asset-backed securities U.S. government sponsored agencies Foreign government obligations Other foreign obligations Long-term investments: Asset-backed securities Total $ $ 130.5 $ 15.0 35.8 74.7 4.0 2.1 262.1 0.1 0.1 262.2 $ 65 2.7 $ 0.2 0.3 2.2 — — 5.4 — — 5.4 $ — — — — — — — — — — $ — $ — — — — — — — — — $ 133.2 15.2 36.1 76.9 4.0 2.1 267.5 0.1 0.1 267.6 The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2020 by contractual maturity date (in millions): Mature in less than one year Mature in one to five years Mature in more than five years Total Available-for-sale investments consist of the following (in millions): Amortized Cost Estimated Fair Value $ $ 130.9 $ 88.1 43.2 262.2 $ 131.5 90.5 45.6 267.6 Short-term investments: Corporate debt securities Municipal obligations Asset-backed securities U.S. government sponsored agencies Foreign government obligations Other foreign obligations Long-term investments: Asset-backed securities December 31, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value $ 203.2 $ 11.5 72.7 105.6 4.7 3.1 400.8 0.1 0.1 1.4 $ 0.1 0.2 0.7 — — 2.4 — — (0.1) $ — (0.1) (0.2) — — (0.4) — — 204.5 11.6 72.8 106.1 4.7 3.1 402.8 0.1 0.1 Total $ 400.9 $ 2.4 $ (0.4) $ 402.9 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories. Gross unrealized losses and associated fair value (in millions) as of December 31, 2019 were: December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Corporate debt securities Asset-backed securities U.S. government sponsored agencies Total Fair Value $ 46.5 $ 17.9 27.5 91.9 $ $ Unrealized Losses Unrealized Losses Unrealized Losses Fair Value $ 2.1 $ 7.0 10.8 19.9 $ $ Fair Value $ 48.6 $ 24.9 38.3 111.8 $ $ — 0.1 — 0.1 0.1 0.1 0.2 0.4 0.1 — 0.2 0.3 66 As outlined in Note 1, we adopted ASU 2016-13 as of January 1, 2020. ASU 2016-13 replaced the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. The factors we considered in our evaluation included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At December 31, 2020, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of December 31, 2020. Included in other current assets are $1.4 million and $2.0 million of interest receivable as of December 31, 2020 and December 31, 2019, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the year ended December 31, 2020, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2020 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in foreign exchange losses, net in the consolidated statements of income. 67 The following is a summary of our forward foreign currency exchange contracts (in millions): Contracts maturing in January through March 2021 to sell foreign currency: Notional value Unrealized loss Contracts maturing in January through March 2021 to purchase foreign currency: Notional value Unrealized gain December 31, 2020 $ $ $ $ 125.3 (0.4) 301.6 0.4 In December 2020, our 4.875% Senior Notes matured and were paid in full. See Note 5. The estimated fair value of our current maturities of long-term debt, excluding leases, as of December 31, 2019 that was not recognized at fair value in the consolidated balance sheets had an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of our long-term debt and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): December 31, 2020 December 31, 2019 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ — $ — N/A $ 424.4 $ 435.5 2 Included in other investments in the consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $0.5 million and $0.3 million as of December 31, 2020 and December 31, 2019, respectively. Also included in other investments in the consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in other income, net in our consolidated statements of income. The carrying value of these investments was $38.4 million and $24.3 million as of December 31, 2020 and December 31, 2019, respectively. 68 4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Balances as of January 1: Goodwill Accumulated impairment losses and write-offs Goodwill, net Acquisitions (see Note 2) Other adjustments (see Note 2) Period increase, net Balances as of December 31: Goodwill Accumulated impairment losses and write-offs 2020 2019 Life Science Clinical Diagnostics Total Life Science Clinical Diagnostics Total $ 250.1 $ 349.2 $ 599.3 $ 234.5 $ 320.5 $ 555.0 (41.8) 208.3 29.8 (2.0) 27.8 (293.4) (335.2) 55.8 264.1 (41.8) 192.7 (293.4) (335.2) 27.1 219.8 — — — 29.8 (2.0) 27.8 15.6 — 15.6 28.7 — 28.7 44.3 — 44.3 277.9 (41.8) 349.2 627.1 (293.4) (335.2) 250.1 (41.8) 349.2 599.3 (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9 $ 208.3 $ 55.8 $ 264.1 Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): Customer relationships/lists Know how Developed product technology Licenses Tradenames Covenants not to compete Other Total definite-lived intangible assets In-process research and development Total purchased intangible assets Weighted- Average Amortization Period (years) 5.51 4.75 14.00 7.73 7.82 3.87 — December 31, 2020 Purchase Price Accumulated Amortization Net Carrying Amount $ $ 116.6 $ 196.6 218.1 65.6 6.6 4.5 0.1 608.1 4.8 612.9 $ (87.2) $ (175.4) (107.1) (37.4) (4.2) (2.0) (0.1) (413.4) — (413.4) $ 29.4 21.2 111.0 28.2 2.4 2.5 — 194.7 4.8 199.5 69 Customer relationships/lists Know how Developed product technology Licenses Tradenames Covenants not to compete Other Total definite-lived intangible assets In-process research and development Total purchased intangible assets Weighted- Average Amortization Period (years) 6.36 5.71 8.31 8.74 8.50 6.01 — December 31, 2019 Purchase Price Accumulated Amortization Net Carrying Amount $ $ 107.2 $ 188.5 144.2 76.0 6.4 3.2 0.1 525.6 0.2 525.8 $ (74.3) $ (162.6) (93.9) (44.4) (3.6) (1.4) (0.1) (380.3) — (380.3) $ 32.9 25.9 50.3 31.6 2.8 1.8 — 145.3 0.2 145.5 No impairment losses related to goodwill and purchased intangibles were recorded in 2020 and 2019. Amortization expense related to purchased intangible assets for the years ended December 31, 2020, 2019 and 2018 was $27.5 million, $23.5 million and $28.3 million, respectively. Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2021, 2022, 2023, 2024, 2025 and thereafter is $28.3 million, $25.1 million, $23.8 million, $20.7 million, $18.7 million, and $78.1 million, respectively. 5. NOTES PAYABLE AND LONG-TERM DEBT Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $207.2 million available for borrowing and usage as of December 31, 2020, which was reduced by $4.9 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. The principal components of long-term debt are as follows (in millions): 4.875% Senior Notes due 2020, net of discount Less unamortized discount and debt issuance costs Long-term debt less unamortized discount and debt issuance costs Finance leases and other debt Less current maturities Long-term debt December 31, 2020 December 31, 2019 $ $ — $ — — 14.1 14.1 (1.8) 12.3 $ 425.0 (0.6) 424.4 15.4 439.8 (426.2) 13.6 70 4.875% Senior Notes In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%. The 4.875% Notes paid a fixed rate of interest of 4.875% per year. We had the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes were not secured and ranked equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants applied at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There were no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. We were in compliance with required debt covenants as of December 31, 2019, and in December 2020 the 4.875% Notes were paid in full, including accrued interest. Credit Agreement In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2020; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2020. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.375% at December 31, 2020, which is based on the 3-month LIBOR. The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of December 31, 2020 and 2019. Maturities of finance leases and other debt at December 31, 2020 were as follows: 2021 - $1.8 million; 2022 - $1.8 million; 2023 - $0.4 million; 2024 - $0.4 million; 2025 - $0.4 million; and 2026 and thereafter - $9.3 million. 6. INCOME TAXES The U.S. and international components of income before taxes are as follows (in millions): U.S. International Income before taxes Year Ended December 31, 2020 2019 2018 $ $ 2,339.7 $ 2,567.9 4,907.6 $ 1,034.0 $ 1,227.1 2,261.1 $ 363.4 149.3 512.7 The provision for income taxes consists of the following (in millions): 71 Current tax expense: U.S. Federal State International Current tax expense Deferred tax expense: U.S. Federal State International Deferred tax expense Non-current tax expense (benefit) Provision for income taxes Year Ended December 31, 2019 2020 2018 $ 69.9 $ 12.0 22.3 104.2 13.0 $ 4.4 23.5 40.9 893.5 54.0 31.5 979.0 18.2 409.7 24.4 16.1 450.2 11.3 $ 1,101.4 $ 502.4 $ 8.8 2.2 30.5 41.5 114.0 6.6 0.3 120.9 (15.4) 147.0 The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows: U. S. statutory tax rate Impact of foreign operations Goodwill impairment U.S. taxation of foreign income U.S. tax reform State taxes Other Provision for income taxes Year Ended December 31, 2019 2018 2020 21.0 % (9.9) — 10.2 — 1.1 — 22.4 % 21.0 % (9.7) — 10.3 — 1.0 (0.4) 22.2 % 21.0 % (4.1) 5.6 15.5 (9.6) 1.7 (1.4) 28.7 % On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million. Our effective income tax rates were 22.4%, 22.2% and 28.7% for the years ended December 31, 2020, 2019 and 2018, respectively. The effective tax rates for the years ended December 31, 2020 and 2019 were driven by the unrealized gain in equity securities that is taxed at approximately 22% as well as the geographic mix of earnings and the taxation of our foreign earnings. The effective tax rate for the year ended December 31, 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits. 72 Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows (in millions): Deferred tax assets: Bad debt, inventory and warranty accruals Other post-employment benefits, vacation and other reserves Tax credit and net operating loss carryforwards Lease obligations Other Total gross deferred tax assets Valuation allowance Total deferred tax assets Deferred tax liabilities: Property and equipment Lease assets Investments and intangible assets Total deferred tax liabilities Net deferred tax liabilities December 31, 2020 2019 $ $ 29.6 $ 29.8 93.5 49.3 44.8 247.0 (44.6) 202.4 23.9 23.0 83.7 48.6 26.0 205.2 (67.2) 138.0 37.0 46.8 2,143.4 2,227.2 (2,024.8) $ 38.4 46.4 1,001.4 1,086.2 (948.2) The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2020, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions decreased by $22.6 million for the year ended December 31, 2020. The valuation allowance for deferred tax assets is as follows (in millions): Beginning balance Additions charged to expenses Deductions from reserves Ending balance 2020 December 31, 2019 $ $ 67.2 — (22.6) 44.6 $ $ 70.8 — (3.6) 67.2 $ $ 2018 66.4 4.4 — 70.8 As of December 31, 2020, our federal, state and foreign net operating loss carryforwards were approximately $26.3 million, $64.5 million and $255.0 million, respectively. Of our foreign net operating losses, $117.8 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our federal and state net operating loss carryforwards, if not utilized, will begin to expire in 2028. As of December 31, 2020, our federal and state tax credit carryforwards were approximately $2.3 million and $37.2 million, respectively. Our federal tax credits, if not utilized, will begin to expire in 2029, and our state tax credits, generally, may be carried forward indefinitely. 73 Federal and state tax laws impose restrictions on the utilization of net operating loss and certain tax credit carryforwards in the event of a change in our ownership as defined by the Internal Revenue Code Sections 382 and 383. Under Section 382 and 383 of the Internal Revenue Code, substantial changes in our ownership and the ownership of acquired companies may limit the amount of net operating loss and research and development credit carryforwards that are available to offset taxable income. The annual limitation would not automatically result in the loss of net operating loss or research and development credit carryforwards but may limit the amount available in any given future period. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): 2020 2019 2018 Unrecognized tax benefits – January 1 $ 39.2 $ 29.8 $ Additions to tax positions related to prior years Reductions to tax positions related to prior years Additions to tax positions related to the current year Settlements Lapse of statute of limitations Currency translation Unrecognized tax benefits – December 31 14.0 (1.5) 3.4 — (0.6) 1.3 7.6 (0.7) 3.0 — (0.4) (0.1) $ 55.8 $ 39.2 $ 54.9 0.6 (20.2) 4.6 (6.8) (1.1) (2.2) 29.8 Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2020, 2019 and 2018 was $14.3 million, $11.2 million and $9.5 million, respectively. Bio-Rad accrued interest and penalties of $2.8 million, $1.7 million, and $(1.4) million for the years ended December 31, 2020, 2019, and 2018, respectively. The total unrecognized tax benefits and interest and penalties of $70.1 million as of December 31, 2020 was partially offset by deferred tax assets of $1.5 million and prepaid taxes of $5.8 million, for a net amount of $62.8 million. As of December 31, 2020, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $17.2 million. Substantially all such amounts will impact our effective income tax rate if recognized. It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate. 74 7. STOCKHOLDERS' EQUITY Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights. Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder. The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock. As a result, the Schwartz family is able to exercise significant influence over Bio-Rad. Changes to Bio-Rad's issued common stock shares are as follows (in thousands): Balance at January 1, 2018 Class B to Class A conversions Issuance of common stock Balance at December 31, 2018 Class B to Class A conversions Issuance of common stock Balance at December 31, 2019 Class B to Class A conversions Issuance of common stock Balance at December 31, 2020 Class A Shares Class B Shares 24,679 30 175 24,884 24 58 24,966 32 75 25,073 5,108 (30) 18 5,096 (24) 18 5,090 (32) 18 5,076 Treasury Shares In November 2017, the Board of Directors authorized a share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. In July 2020, the Board of Directors authorized increasing the Share Repurchase Program to allow the Company to repurchase up to an additional $200.0 million of stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The share repurchase activity under the share repurchase program through open market transactions for the years ended December 31, 2020, 2019 and 2018 are summarized as follows: November 1, 2018 - November 30, 2018 May 1, 2019 - May 31, 2019 June 1, 2019 - June 30, 2019 August 1, 2019 - August 31, 2019 November 1, 2019 - November 30, 2019 March 1, 2020 - March 31, 2020 Number of Shares Purchased Weighted- Average Price per Share Total Shares Repurchased To Date Remaining Authorized Value (in millions) 178,911 $ 25,421 $ 25,977 $ 14,745 $ 22,343 $ 291,941 $ 273.39 291.70 292.01 339.05 358.04 342.55 193,150 $ 218,571 $ 244,548 $ 259,293 $ 281,636 $ 573,577 $ 201.1 193.7 186.1 181.1 173.1 73.1 For the years ended December 31, 2020 and 2019, we used 117,423 and 118,910, respectively, of the repurchased shares in connection with the vesting of restricted stock units and in 2019 we used 19,755 shares in connection with ESPP stock purchases. As of December 31, 2020, $273.1 million remained under the Share Repurchase Program. 75 8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income (loss) included in our consolidated balance sheets and consolidated statements of changes in stockholders' equity consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total Accumulated other comprehensive income (loss) Balances as of January 1, 2019 $ (35.5) $ (14.8) $ 3.3 $ Other comprehensive (loss) income, before reclassifications Amounts reclassified from Accumulated other comprehensive income Income tax effects Other comprehensive income (loss), net of income taxes Balances as of December 31, 2019 Other comprehensive income (loss), before reclassifications Amounts reclassified from Accumulated other comprehensive income $ Income tax effects Other comprehensive income (loss), net of income taxes Balances as of December 31, 2020 $ (36.5) (10.0) — (0.4) (36.9) (72.4) $ 371.9 — (0.9) 371.0 298.6 $ 1.5 1.1 (7.4) (22.2) $ (5.3) 0.3 1.2 (3.8) (26.0) $ 4.8 (0.4) (0.5) 3.9 7.2 $ 4.0 (0.6) (0.8) 2.6 9.8 $ (47.0) (41.7) 1.1 0.2 (40.4) (87.4) 370.6 (0.3) (0.5) 369.8 282.4 All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the consolidated statements of income. Reclassification adjustments are calculated using the specific identification method. 9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS Equity Award Plan We have the 2017 Incentive Award Plan (2017 Plan) for officers and certain other employees. The 2017 Plan authorizes the grant of stock options, restricted stock, restricted stock units, and other types of equity awards to employees. Stock options are granted at exercise prices not less than the fair market value of the underlying common stock on the date of grant and have a maximum term of 10 years. We may issue stock options for either Class A or Class B common stock. Prior to September 2020 grants, equity awards granted vest in increments of 20% per year on the yearly anniversary date of the grant. Starting in September 2020, equity awards granted vest in increments of 25% per year on the yearly anniversary date of the grant. A total of 2,108,050 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2020, there were 1,451,617 shares available to be granted. Employee Stock Purchase Plans Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to the greater of 10% of their compensation or $25,000 annually towards the quarterly purchase of our Class A common stock. The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP. 76 Share-Based Compensation Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards. Share-based compensation expense is allocated to Cost of goods sold, Selling, general and administrative expense, and Research and development expense in the Consolidated Statements of Income. For the year ended December 31, 2020, we recognized share-based compensation expense of $41.6 million of which $3.4 million was allocated to Cost of goods sold, $31.8 million was allocated to Selling general and administrative expense, and $6.4 million was allocated to Research and development expense. For the year ended December 31, 2019, we recognized share-based compensation expense of $35.6 million of which $2.9 million was allocated to Cost of goods sold, $27.9 million was allocated to Selling general and administrative expense, and $4.8 million was allocated to Research and development expense. For the year ended December 31, 2018, we recognized share- based compensation expense of $27.8 million, of which $2.3 million was allocated to Cost of goods sold, $22.0 million was allocated to Selling general and administrative expense, and $3.5 million was allocated to Research and development expense. The income tax benefit related to share-based compensation expense was $6.0 million, $5.6 million and $4.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. We did not capitalize any share-based compensation expense in inventory as it was immaterial. The tax benefit from equity awards vested or exercised during the years ended December 31, 2020, 2019 and 2018 was $11.2 million, $5.4 million, and $5.4 million, respectively. For equity awards, we amortize the fair value on a straight-line basis. All equity awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they occur. Stock Options The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: Expected volatility Risk-free interest rate Expected life (in years) Expected dividend Weighted-average fair value of options granted Year Ended December 31, 2019 2018 2020 27 % 0.31 % 7.4 22 % 1.69 % 7.5 22 % 2.85 % 7.6 — 153.32 $ — 93.96 $ $ — 105.94 Expected volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise. We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero. 77 The following table summarizes stock option activity: Shares Outstanding, December 31, 2019 Granted Exercised Forfeited Outstanding, December 31, 2020 Unvested, December 31, 2020 Exercisable, December 31, 2020 Weighted- Average Exercise Price 162.23 524.30 112.96 269.64 196.29 344,522 $ 22,527 $ (66,085) $ (15,841) $ 285,123 $ Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) 4.64 $ 110.2 73,126 $ 211,997 $ 364.07 138.42 8.35 $ 3.36 $ 16.0 94.2 Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during the years ended December 31, 2020, 2019 and 2018 was approximately $24 million, $12 million and $8 million, respectively. Cash received from stock options exercised during the years ended December 31, 2020, 2019 and 2018 was $3.8 million, $2.6 million and $0.5 million, respectively. As of December 31, 2020, there was $7.0 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a remaining weighted-average period of approximately three years. Restricted Stock Units Restricted stock units are rights to receive shares of company stock. The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant. The following table summarizes restricted stock unit activity: Restricted Stock Units Weighted- Average Grant-Date Fair Value Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding, December 31, 2019 Granted Vested Forfeited Outstanding, December 31, 2020 469,942 $ 112,162 $ (132,745) $ (62,976) $ 386,383 $ 279.14 523.64 246.88 280.97 360.90 1.85 $ 225.2 The total fair value of restricted stock units vested for the years ended December 31, 2020, 2019 and 2018 was $65.0 million, $44.8 million and $40 million, respectively. As of December 31, 2020, there was approximately $125.6 million of total unrecognized compensation cost related to restricted stock units. This amount is expected to be recognized over a remaining weighted-average period of approximately three years. 78 Employee Stock Purchase Plans The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions: Expected volatility Risk-free interest rate Expected life (in years) Expected dividend Weighted-average fair value of purchase rights Year Ended December 31, 2019 2020 41 % 0.5 % 0.25 31 % 2.25 % 0.25 2018 27 % 1.82 % 0.25 — — — $ 94.93 $ 60.39 $ 55.04 The major assumptions are primarily based on historical data. Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero. We sold 47,548 shares for total employee contributions of $16.4 million, 58,717 shares for total employee contributions of $14.3 million and 63,464 shares for total employee contributions of $13.6 million under the 2011 ESPP to employees for the years ended December 31, 2020, 2019 and 2018, respectively. At December 31, 2020, 551,983 shares remain authorized and available for issuance under the 2011 ESPP. 10. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Interest and investment income Net realized gains on investments Other-than-temporary impairment losses on investments Gain on sale of land Gain on divestiture of a division Other expense Other income, net Year Ended December 31, 2019 2020 2018 $ $ (18.2) $ (1.0) 4.6 — (11.7) 1.8 (24.5) $ (30.5) $ (1.5) 5.8 — — 0.1 (26.1) $ (26.6) (1.6) 0.8 (4.1) (5.1) — (36.6) Other-than-temporary impairment losses on equity method investments were recorded in light of the investees' financial condition. 79 11. SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Year Ended December 31, 2019 2018 2020 $ 3,806.3 $ 1,758.7 $ 365.6 138.1 134.2 138.1 Net income Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization Reduction in the carrying amount of right-of- use assets Share-based compensation Gains on dispositions of securities Other-than-temporary impairment losses on investments Changes in fair market value of equity securities Losses on dispositions of fixed assets Gain on sale of land Gain on divestiture of a division Payments for operating lease liabilities Changes in fair value of contingent consideration (Increase) decrease in accounts receivable, net (Increase) decrease in inventories, net (Increase) decrease in other current assets Increase (decrease) in accounts payable and other current liabilities Increase (decrease) in income taxes payable Increase in deferred income taxes (Increase) decrease in other long term assets Increase (decrease) in other long term liabilities Impairment losses on goodwill and long-lived assets Other 37.1 41.6 (0.7) 40.3 35.6 (1.5) 4.6 5.8 (4,495.8) (2,031.0) 1.1 — (11.7) (36.5) (1.0) (15.0) (52.1) (8.4) 124.7 39.0 978.9 (6.4) 26.9 — 4.6 1.2 — — (38.6) (1.6) 1.6 24.2 61.8 10.6 (4.2) 450.2 (1.7) 13.4 — (1.1) Net cash provided by operating activities $ 575.3 $ 457.9 $ Non-cash investing activities: Purchased property, plant and equipment Purchased marketable securities and investments Sold marketable securities and investments $ $ $ 1.2 $ 8.1 $ 4.6 $ — $ 1.4 $ 1.3 $ 80 — 27.8 (1.6) 0.8 (606.2) 2.0 (4.1) (5.1) — (6.2) 59.7 (12.9) (15.3) (45.6) (20.9) 120.9 1.1 (10.0) 292.5 4.9 285.5 5.7 0.8 — 12. COMMITMENTS AND CONTINGENT LIABILITIES Deferred Profit Sharing Retirement Plan We have a profit sharing plan covering substantially all U.S. employees. Contributions are made at the discretion of management. Bio-Rad has no liability other than for the current year’s contribution. Contribution expense was $10.6 million, $16.1 million and $15.9 million for the years ended December 31, 2020, 2019 and 2018, respectively. Purchase Obligations As of December 31, 2020, we had purchase obligations that have not been recognized on our balance sheet of $16.6 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad. The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2020 are as follows: 2021 - $14.1 million, 2022 - $2.1 million, 2023 - $0.1 million, 2024 - $0.1 million, 2025 - $0.1 million and after 2025 - $0.1 million. Long-Term Liabilities As of December 31, 2020, we had obligations that have been recognized on our balance sheet of $134.0 million, which primarily represent recognized long-term obligations for other post-employment benefits as indicated below that are mostly due in more than 5 years, and long-term deferred revenue. Excluded are tax liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded. The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet as of December 31, 2020 were as follows: 2021 - $2.7 million, 2022 - $12.0 million, 2023 - $7.3 million, 2024 - $5.6 million, 2025 - $3.8 million and after 2025 - $102.6 million. Letters of Credit/Guarantees In the ordinary course of business, we are at times required to post letters of credit/guarantees. The letters of credit/ guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.9 million of standby letters of credit/guarantees with financial institutions as of December 31, 2020. Other Post-Employment Benefits In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation as of December 31, 2020 and 2019 of $96.1 million and $81.5 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan. Obligations and Funded Status The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions): 81 Change in benefit obligation: Benefit obligation at beginning of year Service cost Interest cost Plan participants' contributions Actuarial loss Gross benefits paid Plan amendments Settlements Change attributable to foreign exchange 2020 2019 $153.8 $137.3 7.8 0.8 4.1 5.3 (1.7) — (6.4) 13.8 6.9 1.5 3.5 11.9 (2.1) 0.2 (3.8) (1.6) Benefit obligation at end of year 177.5 153.8 Change in plan assets: Fair value of plan assets at beginning year Actual return on plan assets Employer contributions Plan participants' contributions Gross benefits paid Settlements Change attributable to foreign exchange Fair value of plan assets at end of year 72.3 0.6 4.1 4.0 0.2 (6.4) 6.6 81.4 66.9 0.9 4.7 3.8 (0.8) (3.8) 0.6 72.3 Under funded status of plans $(96.1) $(81.5) Amounts recognized in the consolidated balance sheets: Current liabilities (Accrued payroll and employee benefits) Noncurrent liabilities (Other long-term liabilities) Net liability, end of fiscal year $(1.3) (94.8) $(96.1) $(1.1) (80.4) $(81.5) Components of Net Periodic Benefit Cost The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions): 2020 2019 2018 Service costs Interest costs Expected returns on plan assets Amortization of actuarial losses Amortization of prior service costs Settlements Net periodic benefit costs Assumptions $7.8 0.8 (0.7) 1.3 — 1.3 $10.5 $6.9 1.5 (1.2) 1.0 — 0.9 $9.1 $7.5 1.1 (1.1) 1.3 0.1 — $8.9 The above actuarial net losses were primarily based on financial, demographic and experience assumptions. The weighted-average assumptions used in computing the benefit obligations are as follows: 82 Discount rate Compensation rate increase 2020 2019 0.3 % 1.7 % The weighted-average assumptions used in computing the net periodic benefit costs are as follows: Discount rate Expected long-term rate of return on plan assets 0.5 % 1.5 % 1.1 % 1.8 % 2020 2019 2018 0.5 % 1.7 % 0.8 % 1.8 % The accumulated benefit obligation (ABO), an estimate based on the assumption if these plans were to be terminated immediately, as of December 31, 2020 and 2019 was $159.5 million and $138.6 million, respectively. The ABO and fair value of plan assets for these plans with ABO in excess of plan assets were $78.1 million and $66.3 million as of December 31, 2020 and 2019, respectively. In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability as of December 31, 2020 and 2019 was $4.1 million and $3.5 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Concentrations of Labor Subject to Collective Bargaining Agreements At December 31, 2020, approximately seven percent of Bio-Rad's approximately 3,180 U.S. employees were covered by a collective bargaining agreement, which will expire on November 14, 2023. Many of Bio-Rad's non- U.S. full-time employees, especially in France, are covered by collective bargaining agreements. 13. LEGAL PROCEEDINGS We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 14. SEGMENT INFORMATION Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products. We have two reportable segments: Life Science and Clinical Diagnostics. These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities. 83 The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories. Other Operations include our Analytical Instruments segment, and a small miscellaneous operation that was included in a prior acquisition. Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1). Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories. The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters. Segments are expected to manage only assets completely under their control. Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment. Goodwill balances have been included in corporate for segment reporting purposes. Information regarding industry segments at December 31, 2020, 2019, and 2018 and for the years then ended is as follows (in millions): Segment net sales Allocated interest expense Depreciation and amortization Segment profit (loss) Segment assets Capital expenditures Life Science $ 1,231.8 885.9 861.7 Clinical Diagnostics 1,305.2 $ 1,412.0 1,411.8 Other Operations 8.6 $ 13.8 15.9 $ $ $ $ $ 8.0 7.4 7.2 32.8 29.4 34.1 256.3 72.1 28.7 607.3 496.1 16.8 16.6 $ $ $ $ $ 13.8 15.9 16.7 65.1 71.7 72.0 149.1 148.5 (145.7) 1,065.6 1,075.8 43.6 58.9 $ $ $ $ $ 0.1 0.1 0.1 1.0 0.9 0.5 (0.6) (1.5) 0.2 9.5 9.2 3.1 0.6 2020 2019 2018 2020 2019 2018 2020 2019 2018 2020 2019 2018 2020 2019 2020 2019 Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions): 84 Year Ended December 31, 2019 2018 2020 Total segment profit (loss) Foreign currency exchange losses, net Net corporate operating and other expense not allocated to segments Change in fair market value of equity securities Other income, net Consolidated income before income taxes $ 404.8 $ (1.8) 219.1 $ (2.2) (116.8) (2.9) (15.7) (12.9) 4,495.8 24.5 2,031.0 26.1 (10.4) 606.2 36.6 $ 4,907.6 $ 2,261.1 $ 512.7 The following reconciles total segment assets to consolidated total assets (in millions): Total segment assets Cash and other current assets Property, plant and equipment, net, and operating lease right-of-use assets, excluding segment specific balances Goodwill, net Other long-term assets Total assets December 31, $ 2020 1,682.4 $ 1,098.2 2019 1,581.1 1,233.5 52.7 291.9 9,847.4 $ 12,972.6 $ 56.0 264.1 4,863.4 8,008.9 The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions): Europe Asia United States Other (primarily Canada and Latin America) Total net sales Year Ended December 31, 2019 2020 2018 $ $ 857.7 $ 546.5 1,004.8 136.6 2,545.6 $ 770.3 $ 505.0 899.1 137.3 792.0 495.5 863.6 138.3 2,311.7 $ 2,289.4 The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions): Europe Asia United States Other (primarily Canada and Latin America) Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes December 31, 2020 2019 $ 208.6 $ 53.3 454.4 12.0 198.3 51.5 468.7 12.7 $ 728.3 $ 731.2 85 15. RESTRUCTURING COSTS In December 2018, we announced the closure of a small manufacturing facility in France. Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of operations. This restructuring plan is expected to be substantially complete by the first half of 2021. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.1) million, $(0.1) million and $3.9 million and exit costs of $0.1 million, zero and $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively. The amounts recorded were reflected in Cost of goods sold in the consolidated statements of income. The liability of $1.6 million as of December 31, 2020 consisted of $1.5 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other current liabilities in the consolidated balance sheets. From December 2018 to December 31, 2020, total expenses were $4.0 million. The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): Balance as of January 1 Adjustment to expense Cash payments Foreign currency translation losses (gains) Balance as of December 31 2020 2019 $ $ 3.2 — (1.8) 0.2 1.6 $ $ 4.1 (0.1) (0.7) (0.1) 3.2 In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be substantially complete by the first half of 2022. We recorded $(4.8) million and $25.3 million of expenses and adjustments in restructuring charges related to severance and employee benefits for the years ended December 31, 2020 and 2019, respectively. The liability of $2.8 million as of December 31, 2020 was recorded in Accrued payroll and employee benefits in the consolidated balance sheets. The amounts recorded were reflected in Cost of goods sold of $(1.9) million and $4.8 million, in Selling, general and administrative expense of $(1.7) million and $14.4 million and in Research and development expense of $(1.2) million and $6.1 million in the consolidated statements of income for the years ended December 31, 2020 and 2019, respectively. From November 2019 to December 31, 2020, total expenses were $20.5 million. The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): 86 2020 2019 Life Science Clinical Diagnostics Total Life Science Clinical Diagnostics Total Balance as of January 1 Charged to expense $ 6.2 $ — 19.1 $ — 25.3 $ — — $ 6.2 — $ 19.1 — 25.3 Adjustment to expense Cash payments (0.6) (4.7) (4.2) (13.4) (4.8) (18.1) — (0.4) — (0.7) — (1.1) Reserve transferred from prior restructuring plan Foreign currency translation losses Balance as of December 31 — — — 0.3 0.4 — 0.9 $ 0.4 1.9 $ 0.4 2.8 $ 0.1 6.2 $ 0.3 19.1 $ $ 0.7 0.4 25.3 In June 2020, we announced a restructuring plan to consolidate certain finance and administrative activities in Europe and the United States. The restructuring plan is expected to be substantially complete by the first half of 2022. The liability of $2.7 million as of December 31, 2020 was recorded in Accrued payroll and employee benefits in the consolidated balance sheet. The amount reflected in Selling, general and administrative expense was $3.9 million for the year ended December 31, 2020. The following table summarizes the restructuring activities related to the finance and administrative reorganization (in millions): Balances as of January 1 Charged to expense Adjustment to expense Cash payments Foreign currency translation losses Balances as of December 31 $ $ Life Science — 1.5 0.1 (0.5) — 1.1 2020 Clinical Diagnostics — $ 2.3 — (0.8) 0.1 1.6 $ $ $ Total — 3.8 0.1 (1.3) 0.1 2.7 87 16. LEASES For our accounting policies on leases, including leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options. The components of lease expense were as follows (in millions): Twelve Months Ended December 31, 2020 2019 Operating lease cost Finance lease cost: Amortization of right-to-use assets Interest on lease liabilities Total finance lease cost $ $ 45.4 $ 51.4 $0.6 $ $0.8 1.4 $ 0.6 0.9 1.5 3.0 Sublease income The sublease is for a building with a term that ends in 2025, with no options to extend or renew. 3.0 $ $ Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of remeasurements, modifications, impairments and abandonments. Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the years ended December 31, 2020 and 2019. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the years ended December 31, 2020 and 2019. Supplemental cash flow information related to leases was as follows (in millions): Twelve Months Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases Operating cash flows from finance leases Financing cash flows from finance leases Right-of-use assets obtained in exchange for lease obligations: Operating leases Finance leases $ $ $ $ $ 44.4 $ 0.6 $ 0.8 $ 16.1 $ 0.4 $ Supplemental balance sheet information related to leases was as follows (in millions): December 31, Operating Leases Operating lease right-of-use assets Current operating lease liabilities Operating lease liabilities Total operating lease liabilities 2020 2019 202.1 $ 36.5 $ 175.1 211.6 $ $ $ $ 88 47.2 0.9 0.6 28.7 0.2 201.9 35.4 176.0 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. December 31, Finance Leases 2020 2019 Property, plant and equipment, gross Less: accumulated depreciation and amortization Property, plant and equipment, net Current maturities of long-term debt and notes payable Long-term debt, net of current maturities Total finance lease liabilities $ $ $ $ 12.2 $ (5.0) 7.2 $ 0.5 $ 11.0 11.5 $ December 31, 2020 2019 11.4 (4.2) 7.2 0.5 11.2 11.7 9 18 4.2 % 6.5 % 8 16 3.9 % 6.2 % Operating Leases Finance Leases $ $ 43.6 36.5 31.9 27.2 23.2 90.5 252.9 (41.3) 211.6 $ $ 1.3 1.2 1.2 1.2 1.1 14.0 20.0 (8.5) 11.5 Weighted Average Remaining Lease Term Operating leases - in years Finance leases - in years Weighted Average Discount Rate Operating leases Finance leases Maturities of lease liabilities were as follows (in millions): Year Ending December 31, 2021 2022 2023 2024 2025 Thereafter Total lease payments Less imputed interest Total The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over. As of December 31, 2020, operating leases that have not commenced are not material. Operating Leases Under ASC 840, Leases Rents and Leases Rental expense under operating leases was $47.4 million in 2018. Leases were principally for facilities and automobiles. 89 17. QUARTERLY FINANCIAL DATA (UNAUDITED - see accompanying accountants' report) Summarized quarterly financial data for the years ended December 31, 2020 and 2019 are as follows (in millions, except per share data): First Quarter Second Quarter Third Quarter Fourth Quarter $ $ $ $ $ $ $ $ $ $ 571.6 $ 317.4 $ 685.9 $ 22.97 $ 22.72 $ 554.0 $ 311.8 $ 865.2 $ 29.03 $ 28.74 $ 536.9 $ 293.0 $ 966.4 $ 32.59 $ 32.15 $ 572.6 $ 307.8 $ 598.8 $ 20.08 $ 19.86 $ 647.3 $ 367.3 $ 1,314.8 $ 44.24 $ 43.64 $ 560.6 $ 307.0 $ (258.8) $ (8.68) $ (8.68) $ 789.8 460.1 839.2 28.13 27.81 624.5 330.4 553.5 18.50 18.31 2020 Net sales Gross profit Net income Basic earnings per share Diluted earnings per share 2019 Net sales Gross profit Net income (loss) Basic earnings (loss) per share Diluted earnings (loss) per share 18. SUBSEQUENT EVENT On February 3, 2021, we initiated a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan is expected to eliminate a total of approximately 530 positions and the subsequent creation of a total of approximately 325 new positions. We anticipate the restructuring plan will be implemented in phases and is expected to be substantially completed by the end of fiscal year 2022. We estimate that as a result of this restructuring plan we will incur between approximately $125 million and $130 million in total cost, which we anticipate will consist of: (i) approximately $86 million cash expenditures in the form of one-time termination benefits to the affected employees, including cash severance payments, healthcare benefits, and related transition assistance; (ii) approximately $19 million in capital expenditures associated with the restructuring plan; and (iii) between approximately $20 million and $25 million in one-time transition costs, including employee transition costs, supply chain costs and regulatory costs. We anticipate that we will record approximately $80 million to $90 million of the charges related to this restructuring plan in the first quarter of fiscal year 2021. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional charges and future cash payments could occur in relation to the restructuring actions. ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Not applicable. 90 ITEM 9A. CONTROLS AND PROCEDURES (a) Evaluation of Disclosure Controls and Procedures We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level. (b) Management’s Report on Internal Control Over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) or 15(d)-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements. Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2020 using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment and those criteria, management concluded that our internal control over financial reporting was effective as of December 31, 2020. Our internal control over financial reporting has been audited by KPMG, LLP, an independent registered public accounting firm, as stated in their report, which appears in Part II, Item 8 of this Form 10-K. 91 (c) Changes in Internal Control over Financial Reporting Management continuously reviews disclosure controls and procedures, and internal control over financial reporting, and accordingly may, from time to time, make changes aimed at enhancing their effectiveness to ensure that its systems evolve with its business. There were no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the year ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. (d) Inherent Limitations on Effectiveness of Internal Controls Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. ITEM 9B. OTHER INFORMATION None. PART III. ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of Bio-Rad’s definitive proxy statement to be mailed to stockholders in connection with our 2021 annual meeting of stockholders (the “2021 Proxy Statement”) under “Executive Officers,” “Election of Directors,” “Committees of the Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.” Bio-Rad’s Board of Directors has determined that each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K. Each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is also an “independent” director, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange (NYSE) Listed Company Manual. We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal financial officer, controller and all other employees and is available through the Corporate Governance section of our website (www.bio-rad.com). We will also provide a copy of the code of ethics to any person, without charge, upon request, by writing to us at “Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA 94547.” We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on the Corporate Governance section of our website (www.bio-rad.com). 92 ITEM 11. EXECUTIVE COMPENSATION The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2021 Proxy Statement under “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants of Plan-Based Awards,” “Outstanding Equity Awards at Fiscal Year-End,” “Option Exercises and Stock Vested Table,” “Pension Benefits,” “Nonqualified Deferred Compensation Plans,” “Potential Payments on Termination or Change in Control,” “Director Compensation,” “Compensation Committee Interlocks and Insider Participation” and "Pay Ratio Disclosure.” In addition, the information from a portion of the 2021 Proxy Statement under “Compensation Committee Report” is incorporated herein by reference and furnished on this Form 10-K and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of the 2021 Proxy Statement under “Principal and Management Stockholders.” Equity Compensation Plan Information as of December 31, 2020 Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) Weighted-average exercise price of outstanding options, warrants and rights (b)(3) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) 671,506 $ — 671,506 $ 196.29 — 196.29 2,003,600 (2) — 2,003,600 Plan category Equity compensation plans approved by security holders (1) Equity compensation plans not approved by security holders Total (1) Consists of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, and the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan. (2) Consists of 1,451,617 shares available under the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan and 551,983 shares available under the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan. (3) Excludes Restricted Stock Units. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2021 Proxy Statement under “Transactions with Related Persons” and “Committees of the Board of Directors.” ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES The information required to be furnished by this item is incorporated by reference from a portion of the 2021 Proxy Statement under “Report of the Audit Committee of the Board of Directors.” 93 PART IV. ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a)1 Index to Financial Statements – See Item 8 of Part II of this report “Financial Statements and Supplementary Data" on page 39 for a list of financial statements. 2 Schedule II Valuation and Qualifying Accounts All financial statement schedules are omitted because they are not required, or the required information is included in the consolidated financial statements or the notes thereto. 3. Index to Exhibits The exhibits listed below in the accompanying Index to Exhibits are filed or incorporated by reference as part of this report. 94 BIO-RAD LABORATORIES, INC. INDEX TO EXHIBITS ITEM 15(a)3 Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of 1934.” Exhibit No. 3.1 Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc. (1) 3.1.1 Certificate of Amendment to Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc. (1) 3.2 Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. (2) 4.1 Description of Bio-Rad Laboratories, Inc. Class A and Class B Common Stock (3) 10.1 Credit Agreement, dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA National Association, and Mug Bank, Ltd., as co-syndication agents, and Citibank, N.A., and Wells Fargo Bank, N.A., National Association as co-documentation agents. (4) 10.2 Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan. (5)* 10.2.1 First Amendment to the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan (6)* 10.3 Employees’ Deferred Profit Sharing Retirement Plan (Amended and Restated effective January 1, 1997). (7)* 10.4 2007 Incentive Award Plan. (8)* 10.4.1 Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2007 Incentive Award Plan. (9)* 10.4.2 Amendment to the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan. (10)* 10.5 Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (11)* 10.5.1 Global Restricted Stock Unit Award Grant Notice and Global Restricted Stock Unit Award Agreement under 2017 Incentive Award Plan (12)* 10.5.2 Stock Option Grant Notice and Non-Qualified Stock Option Agreement under 2017 Incentive Award Plan (13)* 10.5.3 Global Restricted Stock Unit Award Grant Notice and Global Restricted Stock Unit Award Agreement under 2017 Incentive Award Plan (updated September 2020) (14)* 10.5.4 Stock Option Grant Notice and Non-Qualified Stock Option Agreement under 2017 Incentive Award Plan (updated September 2020) (15)* 10.6 Employment Offer Letter between the Company and Ilan Daskal dated March 15, 2019 (16)* 95 10.7 Employment Offer Letter between the Company and Andrew J. Last dated March 15, 2019 (17)* 10.8 Form of Indemnification Agreement. (18) 21.1 Listing of Subsidiaries. 23.1 Consent of Independent Registered Public Accounting Firm. 31.1 Certification of Chief Executive Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a)). 31.2 Certification of Chief Financial Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a)). 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Labels Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document (1) Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended December 31, 2010. (2) Incorporated by reference to Exhibit 3.1 to Bio-Rad’s Form 8-K filing, dated October 27, 2017. (3) Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form 10-K filing, dated March 2, 2020. (4) Incorporated by reference to the Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 16, 2019. (5) Incorporated by reference to Exhibit 10.9 to Bio-Rad's June 30, 2011 Form 10-Q filing, dated August 4, 2011. (6) Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017. (7) Incorporated by reference to Exhibit 10.6 to Bio-Rad’s September 30, 1997 Form 10-Q filing, dated November 13, 1997. (8) Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form S-8 filing, dated July 30, 2007. (9) Incorporated by reference to Exhibit 10.8.1 to Bio-Rad’s September 30, 2009 Form 10-Q filing, dated November 4, 2009. (10) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s March 31, 2014 Form 10-Q filing, dated May 8, 2014. 96 (11) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017. (12) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017. (13) Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017. (14) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated October 30, 2020. (15) Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated October 30, 2020. (16) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 2, 2019. (17) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 22, 2019. (18) Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated August 7, 2017. * Indicates a management contract or compensatory plan or arrangement. Item 16. FORM 10-K SUMMARY Not applicable. Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SIGNATURES BIO-RAD LABORATORIES, INC. By: /s/ Ilan Daskal Ilan Daskal Executive Vice President, Chief Financial Officer Date: February 12, 2021 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 97 Principal Executive Officer: /s/ Norman Schwartz (Norman Schwartz) Principal Financial Officer: /s/ Ilan Daskal (Ilan Daskal) Principal Accounting Officer: /s/ Ajit Ramalingam (Ajit Ramalingam) Other Directors: /s/ Jeffrey L. Edwards (Jeffrey L. Edwards) Chairman of the Board, President and Chief Executive Officer February 12, 2021 Executive Vice President, Chief Financial Officer February 12, 2021 Senior Vice President, Chief Accounting Officer February 12, 2021 Director February 12, 2021 /s/ Gregory K. Hinckley Director February 12, 2021 (Gregory K. Hinckley) /s/ Melinda Litherland (Melinda Litherland) /s/ Arnold A. Pinkston (Arnold A. Pinkston) /s/ Alice N. Schwartz (Alice N. Schwartz) Director Director Director February 12, 2021 February 12, 2021 February 12, 2021 98 BIo-rad LaBoratorIeS corPorate InFormatIon AnnuAl MeetingThe Annual Meeting of Stockholders will be virtual-only and held on Tuesday, April 27 at 4 PM, Pacific Time. Please refer to our proxy statement for details on how to connect to the meeting.Bio-Rad will provide without charge to each stockholder, upon written request to the Secretary, a copy of its 2020 Annual Report filed with the Securities and Exchange Commission on Form 10-K.trAnsfer AgentComputershare c/o Shareholder Services 462 South 4th Street, Suite 1600 Louisville, KY 40202 www.computershare.comAuditorsKPMg llPCoMMon stoCKTraded on the New York Stock ExchangeClass A Common Stock Symbol BioClass B Common Stock Symbol BiobOther SeNIOr executIveSJim BarrySenior Vice President, Quality Systems Lee BoydSenior Vice President, Global Commercial Operations, Asia Pacificcolleen coreyExecutive Vice President, Global Human ResourcesDiane DahowskiExecutive Vice President, Global Supply Chain Kurt DeLangheSenior Vice President, Global Commercial Operations, Europe, Middle East, AfricaSimon MaySenior Vice President, Digital Biology Grouperik MolitorSenior Vice President, Global Technology & SystemsGeoffrey Schwartz Senior Vice President, Global Commercial Operations, AmericasJonathan SeatonSenior Vice President, Corporate Business DevelopmentDirectorsNorman schwartz Chairman of the BoardJeffrey L. edwards DirectorGregory K. HinckleyDirectorMelinda LitherlandDirectorArnold A. PinkstonDirectorAlice N. schwartzDirectorofficersNorman schwartz President and Chief Executive Officer Andrew Last Executive Vice President, Chief Operating Officerilan DaskalExecutive Vice President, Chief Financial OfficerMichael crowley Executive Vice President, Global Commercial Operationstimothy s. ernstExecutive Vice President, General Counsel & SecretaryAnnette tumoloExecutive Vice President, President, Life Science GroupDara WrightExecutive Vice President, President, Clinical Diagnostics Groupronald HuttonVice President, TreasurerAjit ramalingamSenior Vice President, Chief Accounting OfficerCORPORATE OFFICES 1000 Alfred Nobel Drive Hercules, California 94547 USA +1 510-724-7000 PHONE +1 510-741-5817 FAX www.bio-rad.com 

Continue reading text version or see original annual report in PDF format above